Kinetic Characterization Of Listeria Monocytogenes 2-C-Methyl-D-Erythritol 4-Phosphate Cytidylyltransferase (cms) Enzymes Using High Performance Liquid Chromatography (hplc) by Oblazny, Mark
Illinois State University
ISU ReD: Research and eData
Theses and Dissertations
10-20-2017
Kinetic Characterization Of Listeria
Monocytogenes 2-C-Methyl-D-Erythritol
4-Phosphate Cytidylyltransferase (cms) Enzymes
Using High Performance Liquid Chromatography
(hplc)
Mark Oblazny
Illinois State University, moblazn@ilstu.edu
Follow this and additional works at: https://ir.library.illinoisstate.edu/etd
Part of the Biochemistry Commons, and the Chemistry Commons
This Thesis and Dissertation is brought to you for free and open access by ISU ReD: Research and eData. It has been accepted for inclusion in Theses
and Dissertations by an authorized administrator of ISU ReD: Research and eData. For more information, please contact ISUReD@ilstu.edu.
Recommended Citation
Oblazny, Mark, "Kinetic Characterization Of Listeria Monocytogenes 2-C-Methyl-D-Erythritol 4-Phosphate Cytidylyltransferase
(cms) Enzymes Using High Performance Liquid Chromatography (hplc)" (2017). Theses and Dissertations. 812.
https://ir.library.illinoisstate.edu/etd/812
KINETIC CHARACTERIZATION OF LISTERIA MONOCYTOGENES 2-C-METHYL-D-
ERYTHRITOL 4-PHOSPHATE CYTIDYLYLTRANSFERASE (CMS) ENZYMES         
USING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
 
 
Mark Oblazny 
94 Pages 
Infectious diseases, with increasing prevalence of antibiotic resistant bacteria, coupled 
with the declining rate in discovery of antimicrobial agents, impose one of the most significant 
threats to human health. Here we identify 2-C-methyl-D-erythritol 4-phosphate 
cytidylyltransferase (CMS) as a valid target for antibiotic development which is an enzyme in 
pathogenic organisms that leads to the biosynthesis of isoprene precursor molecules. Isoprene 
molecules are one of nature’s most common building blocks that are vital to many biological 
metabolic processes and are synthesized via the mevalonic acid dependent (MVA), or 
methylerythritol phosphate (MEP) pathway. Vertebrates utilize the MVA pathway, while many 
pathogenic bacteria use the MEP pathway for isoprenoid biosynthesis. With separate pathways 
expressed between vertebrates and bacteria, the MEP pathway is an attractive target for the 
development of effective novel antimicrobial therapeutics. This report kinetically characterizes 
two putative isoforms of CMS from Listeria monocytogenes. This study validates a previously 
developed high performance liquid chromatography (HPLC) method for the kinetic 
characterization of cytidylyltransferase enzymes. Structural homology and sequence analysis of 
both putative isoforms of CMS provide new evidence suggesting the lmo0235 gene encodes a 
CMS and the lmo1086 gene from Listeria monocytogenes encodes a putative ribitol 5-phosphate 
cytidylyltransferase. 
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CHAPTER I: INTRODUCTION 
2-C-methyl-D-erythritol-4-phosphate Cytidylyltransferase 
2-C-methyl-D-erythritol-4-phosphate cytidylyltransferase (CMS EC # 2.7.7.60) is a 
member of the cytidylyltransferase family of enzymes, and is essential to many prokaryotic 
organisms. CMS is an enzyme that catalyzes the third reaction in the methylerythritol phosphate 
(MEP) pathway, a biosynthetic pathway for production of isoprenes. Other names the enzyme is 
referred to in literature are IspD (isoprenoid synthesis domain containing), MEP 
cytidylyltransferase, CDP-ME synthetase, or YgbP (open reading frame/gene). The MEP 
pathway forms the products isopentenyl diphosphate (IPP) and dimethylallyl diphosphate 
(DMAPP), which are the phosphate charged precursor molecules of isoprenes, shown in Figure 
1. The pathway is also commonly known as the 1-deoxy-D-xylulose 5-phosphate (DOXP/DXP) 
pathway. The alternative pathway for isoprenoid synthesis is the mevalonic acid (MVA) 
dependent pathway, which is present in vertebrates (Figure 2). The MVA pathway does not 
contain the enzyme CMS, thus making it a great target for antimicrobial therapeutic 
development. 
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Figure 1. Methylerythritol Phosphate Pathway (MEP). Pathway for the biosynthesis of 
isoprenoid precursor molecules isopentenyl diphosphate (IPP) and dimethylallyl diphosphate 
(DMAPP). Each “P” symbolizes a phosphate group. “CDP” represents Cytidine diphosphate. 
Enzyme names: DXS is DOXP synthase, DXR is DOXP reductase, CMS is 2-C-methyl-D-
erythritol-4-phosphate cytidylyltransferase, CDP-ME kinase is 4-diphosphocytidyl-2-C-methyl-
D-erythritol kinase, MCS is 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase, HDS is 4-
hydroxy-3-methylbut-2-en-1-yl diphosphate synthase, and HDR is 4-Hydroxy-3-methylbut-2-
enyl diphosphate reductase. Pathway was made using ChemDraw. 
 
 
Figure 2. Mevalonic Acid (MVA) Dependent Pathway For Isoprenoid Synthesis In Vertebrates. 
Each “P” symbolizes a phosphate group. HMG stands for 3-hydroxy-3-methyl-glutaryl. CoA is 
coenzyme A. MVA is mevalonate-3-phosphate-5-kinase. PMVA is phosphomevalonate kinase. 
DPMVA ismevalonate-5-pyrophosphate decarboxylase. Pathway constructed using ChemDraw. 
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Isoprenoids 
Isoprenes, the single unit of terpenes, are one of the most common structural motifs in 
biological systems and one of nature’s most common building blocks. Simply, these isoprenoid 
molecules are necessary for an organism’s survival and have over 35,000 primary and secondary 
metabolites (Chang & Keasling, 2006). Isoprene units can form carbon skeletons ranging from a 
few linkages to thousands. Isoprenoids are used in many other biosynthetic pathways and build 
vital metabolites for functionality.  Some important metabolites include sterols, vitamins, heme, 
and ubiquinone (Coenzyme Q) (Ad Heuston, Begley, Gahan, Hill, & Ie, 2012). Sterols are the 
third class of lipids that are required for a plethora of cellular processes. Sterols are components 
of plasma membranes found abundantly in eukaryotic cells but less in prokaryotic cells. They 
play a role in sustaining a liquid ordered state of the membrane that preserves cell membrane 
fluidity and functionality by creating lipid “rafts” (Simons & Ehehalt, 2002). Ubiquinone is 
found in mitochondrial membranes and plasma membranes of prokaryotes which serves as an 
electron carrier in the electron transport chain for the eventual synthesis of ATP.  
Isoprene is the most abundant hydrocarbon measurable in the breath of humans, which 
emphasizes its significance in biological systems (Gelmont, Stein, & Mead, 1981). The isoprene 
emission accounts for around one-third of all hydrocarbons released into the atmosphere by all 
organisms (King et al., 2010).  Molecules that are biosynthetically synthesized from isoprene 
subunits play crucial roles in an organism, such as cell signaling, cell maintenance, enzyme 
cofactors, and cell wall synthesis. An organism without some of these functions will undergo cell 
death since it will not be able to maintain homeostasis. With the absence of isoprene derivatives, 
major metabolic pathways will be halted, thus making CMS a great potential target for antibiotic 
therapeutics.  
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Isoprene subunits are used in industry today to produce synthetic forms of rubber found 
in many daily products. Isoprene-derived compounds are found in common household items 
such as cosmetics, food, baby bottles, tires, and essential oils. These compounds are responsible 
for some of the pleasant aromas in some cosmetic products. Studies are starting to research 
terpenoids for their anti-cancer and anti-inflammatory properties (Sharma, Thulasingam, & 
Nagarajan, 2017). Terpenes are being evaluated in cannabis as they can become useful in the 
pharmaceutical industry.  
Several pathogenic organisms such as Mycobacterium tuberculosis, which causes 
tuberculosis (TB), Plasmodium falciparum, the parasite that causes malaria, and Listeria 
monocytogenes, which leads to listeriosis, use the MEP pathway for isoprene biosynthesis. 
Listeriosis, commonly known as food poisoning, affects about 1,600 individuals per year and is 
most likely to sicken pregnant women and newborns (Center for Disease Control and Prevention 
[CDC], 2017). Tuberculosis is one of the top 10 causes of death worldwide. In 2015, 10.4 
million people fell ill with TB and 1.8 million died from the disease (World Health Organization 
[WHO], 2017). In 2015, there were 214 million cases of malaria worldwide resulting in an 
estimated 438,000 deaths (WHO, 2017). These are just a few organisms of interest although 
many more can be included as potential targets. Since the biosynthesis of isoprenoids occur in 
separate pathways it opens up possibilities for next generation antibacterial therapeutics that can 
target CMS without having adverse effects on vertebrates (humans) which utilize the 
mevalonate-dependent pathway. Growing antibiotic resistance is becoming an issue of concern 
which makes the development of novel antibiotics a pressing issue for human society. An 
enzyme target like CMS may not lead to just curing diseases but improving the quality of life of 
millions of individuals around the world.. 
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Listeria Monocytogenes 
 Listeria monocytogenes is the pathogenic gram-positive bacterium that causes listeriosis. 
Gram-positive bacteria simply means the bacterial cell wall contains peptiodoglycan. Listeria is 
very tough to evade as it has the capability to grow in absence or presence of oxygen (facultative 
anoerobe), and to replicate and grow at 0 °C (Ramaswamy et al., 2007). This is of great concern 
as typical refrigeration temperatures around 0 °C to prevent bacterial growth, although this 
temperature will not affect the ability of Listeria monocytogenes to grow. The bacteria are motile 
with a flagella at temperatures less than 30 °C but not usually under host biological conditions of 
about 37 °C (Gründling, Burrack, Bouwer, & Higgins, 2004).  With the bacteria’s ability to grow 
in low temperatures, it is recognized as a hazard to the food industry. Listeria monocytogenes has 
been associated with such foods as raw milk, pasteurized milk, cheeses, raw vegetables, raw and 
cooked poultry, and raw meats. It is known to cause food-borne illness, enter and escape cells 
frequently, and evade the body’s immune response systems. It seems that Listeria originally 
evolved to invade membranes of the intestines, as an intracellular infection, and developed a 
chemical mechanism to do so. This involves the bacterial protein internalin that acts as a ligand 
that attaches to a protein, cadherin on the intestinal cell membrane and allows the bacteria to 
invade the cells through a zipper mechanism (Robbins et al., 1999). A zipper mechanism is a 
form of phagocytosis when a cell engulfs surrounding material and allows it to flow freely in a 
small vacoule inside a cell. Once inside the cell, Listeria is able to escape the vacuole and enter 
the cytosol through the use of listeriolysin O (LLO) (Portnoy, Auerbuch, & Glomski, 2002). 
Motility in the intracellular space is due to actin assembly-inducing protein (ActA) which allows 
the bacteria to recruit the host cell's actin polymerization machinery to polymerize the 
cytoskeleton to give the bacterial cell motility (Portnoy et al., 2002). The same ActA mechanism 
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also allows the bacteria to travel from cell to cell.  Although not one of the most common 
diseases, listeriosis is of concern for pregnant patients, neonates, elderly, and 
immunocompromised individuals.  
While CMS is a promising target for novel drug therapeutics, it is far from being well 
understood and is very understudied. Much like bacterial cell wall biosynthesis, which has been 
so successfully targeted by antibacterial agents, the MEP pathway is essential for microbial 
growth, and none of the enzymes of this pathway are present in mammalian cells. Some of the 
recent discoveries for antibiotic development generally proceed through five phases, including 
target identification, target validation, lead molecule identification, lead molecule optimization, 
and preclinical and clinical trials. This thesis project will focus on target identification, which 
will be choosing the CMS enzyme in the MEP pathway, and target validation studies by 
obtaining kinetic information. In order to design effective CMS therapeutics, foundational 
kinetic research must be performed.  
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Structure Overview of E. coli CMS 
The E. coli CMS isoform is a good model for Listeria monocytogenes CMS 1086 and 
CMS 0235. Although using the E. coli as a model for bi-functional CMS enzymes that contain 2 
functions due to gene fusion events is less comparable, although this is not the case for CMS 
1086 and CMS 0235. Using CMS from E.coli as a model, the enzyme is a homodimeric protein 
with an important structural interlocking arm (Richard et al., 2004). This interlocking arm is 
essential to protein stability and function. The homodimer of the E. coli variant contains two 
active sites with one on each identical subunit and the interlocking arm lodges itself into the 
active site of the neighboring subunit to perform catalysis. The interlocking arm domain is a 
small segment of residues 137-159, while the larger domain is the globular domain with residues 
1-136 and 160-236. The protein contains a modified Rossmann motif that is commonly found in 
proteins that bind nucleotides. A Rossmann motif is an alternating pattern of parallel β-sheets 
connected by α-helices in a βαβ folding pattern (Hanukoglu, 2015). The E. coli CMS appears to 
contain this motif with the exception of one β-sheet oriented in an antiparallel direction (Figure 
3). The interlocking arm region contains a series of β-sheets from one subunit interacting in an 
antiparallel orientation with the β-sheets of the neighboring subunit.  
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Figure 3. Structure of E. coli CMS Monomeric Unit Displaying the Rossmann Motif (PDB 
1INJ). Rossmann fold β-sheets are numbered, 1-7. Structure image made using RasMol, α-
helices are yellow, β-sheets are green, and the interlocking arm region is red. 
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Ribitol 5-phosphate Cytidylyltransferase (RCT)  
 Ribitol 5-phosphate cytidylyltransferase (TarI or RCT EC # 2.7.7.40) catalyzes a 
similar reaction to CMS and is part of the pathway necessary for biosynthesis of wall techoic 
acids (WTAs) in gram positive bacteria. The reaction catalyzed is the conversion of CTP and 
ribitol 5-phosphate to CDP-ribitol, a vital intermediate in the biosynthesis of WTA (Baur, 
Marles-Wright, Buckenmaier, Lewis, & Vollmer, 2009). The WTA synthesis pathway is separate 
from the MEP pathway, but upon closer analysis RCT and CMS enzymes display structural 
similarities. Inhibition of RCT is a potential target for antibiotic development through inhibition 
of the WTA pathway. The structure of RCT is similar to CMS, which is a homodimer protein 
containing the interlocking arm and Rossmann like motif, however only three structures have 
been solved for a ribitol 5-phosphate cytidylyltransferase.  
Cell Wall Techoic Acid 
Teichoic acids are the major cell wall components of the pathogenic bacterial 
Staphylococcus aureus, Staphylococcus saprophyticus, and Listeria monocytogenes. Teichoic 
acids were discovered in 1958 by Armstrong and co-authors (Armstrong, Baddiley, Buchanan, 
Carss, & Greenberg, 1958). Techoic acids are made up of anionic polymers of glycerol 
phosphate or ribitol phosphate, with phosphodiester linkages (Neuhaus & Baddiley, 2003). Wall 
teichoic acid (WTA), which is covalently linked via a phosphodiester bond to C-6 of N-
acetylmuramic acid, plays many roles in the peptidoglycan layer. WTA decorates the outer cell 
wall and represents about 60% of the total cell wall mass (Neuhaus & Baddiley, 2003). WTA 
contains anionic character from phosphate groups that can sequester cations from the 
surrounding environment (Swoboda, Campbell, Meredith, & Walker, 2010). This provides the 
cell with a reservoir of cations that can be easily accessible for the cells in times of stress. It has 
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been suggested that cell wall teichoic acids can create localized changes in pH, indirectly 
modulating the function of some enzymes (Biswas et al., 2012). The polyribitol cell WTA is able 
to contain modifications on the free hydroxyl groups of ribitol that would allow for additional 
cell regulation mechanisms. The WTA is the cell’s protective layer that stabilizes the cell 
membrane and provides docking sites for proteins and nutrients as well (Swoboda et al., 2010). 
S. aureus strains that do not express WTAs are unable to adhere to nasal, kidney, and spleen 
epithelial cells, indicating the reduced virulence of the pathogen (Weidenmaier et al., 2005). 
WTA is not vital for cell proliferation but it has been seen to play roles in antibiotic resistance 
and increased virulence. WTAs are structurally diverse between organisms and contain various 
modifications. A study was performed on the analysis of Listeria monocytogenes WTAs 
confirming the presence of a polyribitol-phosphate backbone (Eugster & Loessner, 2011). 
Disrupting the biosynthesis of WTAs is a promising target for unique antimicrobial therapeutics. 
The pathway of WTA synthesis is not well characterized and many of the mechanisms by which 
WTA is able to regulate cell physiology are still ambiguous. Many genes that encode enzymes 
within the techoic acid and peptidoglycan synthesis pathways have yet to be identified.  
β-lactam Antibiotics 
 β-lactams are one of the most successful and widely used antibiotics in history (Geddes, 
Klugman, & Rolinson, 2007). This class of antibiotics is, however, becoming less effective with 
emerging resistance through multiple mechanisms. A pathway of resistance consists of a β-
lactamase that inactivates β-lactam antibiotics by hydrolyzing the β-lactam ring (Drawz & 
Bonomo, 2010). Despite the emergence of β-lactamase inhibitors that have restored efficacy of 
the β-lactam class of antibiotics, other mechanisms of antibiotic resistance have emerged. 
Methicillin resistant Staphylococcus aureus (MRSA) has achieved β-lactam resistance through 
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additional mechanisms, including penicillin-binding protein (PBP2A) which is not susceptible to 
β-lactam antibiotics. PBP2A is a transpeptidase that functions in secondary crosslinking of the 
peptidoglycan layer (PG). A secondary transpeptidase PBP4 is also found at the division septum, 
which generates highly crosslinked PG for cell division. The division septum is the middle 
portion of the cell after elongation occurs, and this is the region where cell replication is 
occurring. Localization of the PBP4 at the division septum is reliant on the existence of cell 
WTA (Atilano et al., 2010). This implies that WTAs play roles in the emergence of antibiotic 
resistance in MRSA, and inhibition of WTA synthesis can become the forefront in fighting 
antibiotic resistant bacteria. 
Research Objectives 
 The primary goal of this research was to characterize CMS in the MEP pathway from 
Listeria monocytogenes responsible for isoprenoid synthesis. Characterization of the enzymes 
included, conducting kinetic experiments to extrapolate kinetic constants Km and Vmax. This 
research lays a foundation for the development of potential inhibitors for CMS enzymes. A 
recently developed HPLC method for the characterization of cytidylyltransferase enzymes was 
utilized for the characterizations of CMS 0235 and 1086 (Brault Thesis, 2016). The importance 
of isoprenoids in biology and industry are apparent with a broad range of applications as 
discussed earlier. A secondary goal was to identify and explain some of the variation in catalytic 
activity of CMS 0235 and 1086 by using multiple sequence alignments and structural homology 
modeling. The objectives were to detect highly conserved amino acids among CMS enzymes and 
indicate areas that would compromise CMS activity of the enzymes. By incorporating protein 
modeling we can identify regions of secondary structure that are vital for functionality and 
compare and contrast secondary and tertiary structure elements. 
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CHAPTER II: METHODS 
Cell Transformation of lmo0235 
Plasmid DNA containing the gene for CMS 0235 (pet45b-lmo0235) from Shilpa Maroju 
(Maroju Thesis, 2008) was inserted into BL21 (DE3)CodonPlus RIL E. coli cells (Agilent), 
which are in the class of B strain E. coli. These cells encode a T7 RNA polymerase from 
bacteriophage that uses double stranded DNA to catalyze the synthesis of RNA in the 5’-3’ 
direction. The T7 polymerase recognizes the lacUV5 promoter sequence 
TAATACGACTCACTATAG and does not require any additional activators, thus making it 
ideal for high-level protein expression systems. Another advantage of using this strain of E. coli 
is these cells contain a ColE1-compatible, pACYC-based plasmid containing extra copies of the 
argU, ileY, and leuW tRNA genes. Due to the increased expression of a heterologous protein 
using the T7 polymerase, some rare tRNAs may be depleted and stall protein expression. These 
cells are engineered to be deficient in Lon and OmpT protease proteins which are known to 
degrade recombinant proteins (Agilent Technologies, 2017). 
BL21 (DE3)CodonPlus RIL E. coli cells (Agilent) were placed on ice and allowed to 
thaw slowly and 50 μL of cells were then placed in a 14 mL sterile polypropylene tube, 
containing 1 μL of pet45b-lmo0235. The mixture of DNA and cells were incubated on ice for 30 
minutes then placed in a 42 oC water bath for 30 seconds to heat shock the cells. This allows for 
the membranes to become more fluid and porous allowing the plasmid DNA to enter the host 
cell. Following the heat shock phase, the tube is placed back on ice for 2 minutes as a recovery 
phase. Following the recovery phase an additional 1 mL of LB medium is pipetted into the tube 
and incubated in a shaker at 37 oC for about 1 hour while shaking at about 250 rpm. The cells 
were plated on agar plates containing 100 μg/mL ampicillin and 34 μg/mL chloramphenicol. The 
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plates contained the antibiotics to serve as a selection process for the cells. Two plates were used, 
one contained 20 μL and the other 200 μL aliquots of cells, since transformation efficiency is 
unknown. The cells are spread using sterile glass beads and plates are incubated overnight at 37 
oC. Colonies that grow on the plates are presumably the cells that have uptaken the pet45b-
lmo0235 plasmid containing the antibiotic resistant genes. 
Cell Transformation of lmo1086 
 Plasmid DNA containing the lmo1086 gene for CMS 1086 (pet45b-lmo1086) from 
Shilpa Maroju (Maroju Thesis, 2008) was inserted into ArcticExpress (DE3) RIL competent 
cells (Agilent) for improved protein expression. When using high-level expression systems for 
heterologous protein, it can result in the synthesis of misfolded and insoluble protein. When 
lmo1086 is expressed in BL21 (DE3) CodonPlus RIL E. coli cells, the protein produced is 
insoluble and is not suitable for kinetics assays (Maroju Thesis, 2008). Some labor intensive in 
vitro methods call for the unfolding and refolding of these insoluble aggregate proteins. To 
bypass this, ArcticExpress (DE3) RIL cells can be utilized to yield properly folded soluble 
recombinant protein. ArcticExpress cells have been specially engineered to express the 
GroEL/GroES chaperonin complex for improved protein folding activity at low temperatures. 
The cells contain the Oleispira antartica Cpn10 and Cpn60 chaperonins that have optimal 
activity at 4-12 oC. The ArcticExpress strain also contains a T7 polymerase and lacUV5 
promoter for protein expression (Agilent Technologies, 2017).   
 The cell transformation process is similar to the lmo0235 procedure. An important 
modification is the antibiotics used for the selection process. For the lmo1086 in ArcticExpress 
(DE3) RIL cells, the antibiotics streptomycin, gentamycin, and ampicillin must be used. 
Gentamyacin resistant genes are on the plasmid containing the Cpn10 and Cpn60 genes for the 
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chaperonin proteins (Agilent Technologies, 2017). In order to retain the plasmid containing these 
genes the cells must be grown in medium containing gentamycin. 
Expression of lmo0235 in BL21 (DE3)CodonPlus RIL E. coli Cells 
 Following the overnight incubation of cells that are plated on agar plates, colonies were 
picked for large-scale protein synthesis. A colony containing pet45b-lmo0235 was picked and 
placed into an appropriately labeled 14 mL polypropylene tube containing 5 mL of LB medium. 
The sample was then inoculated with 5 μL chloramphenicol (34 mg/mL) and 5 μL of ampicillin 
(100 mg/mL). The tube was placed into the shaker at 37 oC at 250 RPM and incubated for about 
5 hours. After the 5 hour growth period the contents of the tube were transferred to 50 mL of LB 
medium containing 50 μL of chloramphenicol (34 mg/mL) and 50 μL of ampicillin (100 
mg/mL), then allowed to incubate in shaker at 37 oC overnight. Following the overnight 
incubation, cells were transferred into an Erlenmeyer flask of 1 L LB medium containing 1 mL 
of the antibiotics chloramphenicol (34 mg/mL) and ampicillin (100 mg/mL). The flask was 
returned to the shaker and incubated for another 3 hours at 37 oC. After 3 hours a 1 mL sample 
was removed from the cell culture into a polypropylene microcentrifuge tube and cells were 
pelleted at 14,000 RPM for 1 minute using a microcentrifuge (FORCE Micro); this will serve as 
a control, known as the uninduced sample. The supernatant was discarded and the pellet 
resuspended in 1X SDS buffer solution then stored at -20 oC. The 1 L culture was then induced 
with 0.05 g of IPTG, (Molecular Biologicals International Inc.), and placed back in the shaker 
for 3 hours. During this final 3 hour time period the cells are forced into a high level of 
expression of the CMS enzyme. At this point another 1 mL sample was removed and treated like 
the previous uninduced control sample. The 1 L culture was then centrifuged at 5,000 RPM for 5 
minutes at 4 oC using a J25-I centrifuge and a JLA-10.5 rotor. Following centrifugation, pelleted 
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cells were resuspended in 20 mL of cell lysis buffer (50 mM Tris, 100 mM NaCl at pH 7.5), 
frozen at -20 oC; for analysis, cells were thawed then lysed using a French Press, and used for 
protein purification.  
Expression of lmo1086 in ArcticExpress (DE3) Competent E. coli Cells 
 For high level protein expression, a colony was picked from the agar plate and placed 
into a 14 mL polypropylene tube containing 5 mL of LB medium with 50 μg/mL ampicillin, 20 
μg/mL gentamycin, and 75 μg/mL streptomycin. The culture sample was incubated in the shaker 
at 37 oC for 5 hours, and then transferred to a 50 mL flask of LB medium containing the same 
antibiotics and allowed to incubate overnight. After the overnight incubation, the culture was 
transferred into 1 L of LB medium that contains 50 μg/mL ampicillin, 20 μg/mL gentamycin, 
and 75 μg/mL streptomycin and incubated in the shaker for an additional 3 hours at 37 oC. A 
sample was removed as the uninduced form of the cells and saved for SDS-PAGE analysis. The 
1 L culture flask was then induced with 0.05 g of IPTG and placed in the cold room at 4-12 oC 
for 24 hours. Following the 24 hour time period, a sample again was obtained as the induced 
sample and analyzed using SDS-PAGE to provide evidence of successful protein production. 
Cells were centrifuged and placed in buffer following the same procedure as used for the 
lmo0235 cells. 
Lmo0235 and lmo1086 Cell Lysis and Purification  
 Cells were subjected to the French Press (Spectronic Instruments) for cell lysis. A 20 mL 
sample of cells was thawed and dosed with 500 μL of inhibitor cocktail (Sigma Aldrich) to 
prevent protein degradation. The cells were placed into the French Press at 10,000 psi to lyse the 
cells and release the soluble enzymes (lmo0235 and lmo1086) into the buffer. A 1 mL sample 
was removed, labeled as crude extract, and frozen at -20 oC for further protein analysis. The 
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remaining crude extract was then centrifuged at 15,000 RPM for 15 minutes at 4 oC using a J25-I 
centrifuge and a JA-17 rotor. Another 1 mL sample was removed and stored as supernatant at      
-20 oC, and the pellet was discarded.   
A high affinity cobalt TALON column (Clontech) was used to purify CMS from the 
supernatant after centrifugation. Three milliliters of washed TALON Metal Affinity Resin, 
stored in 20% ethanol, was poured into a column and 50 mL of lysis buffer was flowed through 
to equilibrate the column. The supernatant was diluted with buffer to approximately 50 mL for 
enhanced column flow rate. The diluted supernatant was passed through the Cobalt TALON 
Metal Affinity column. The CMS enzymes contain a 6x-His tag on the N-terminal end. The 
histidine tag on the enzymes interacts with the cobalt on the resin beads and the enzymes are 
retained on the cobalt column. Approximately 40 mL of lysis buffer was passed through the 
column to remove any unbound proteins and labeled as column flow through (C.F.T). Following 
the C.F.T, 30 mL of 10 mM imidazole in lysis buffer was passed through the column to remove 
any weakly bound proteins from the cobalt column. This fraction is labeled as the column wash. 
Finally, 10 mL of 150 mM imidazole elution buffer in lysis buffer was passed through the 
column to remove the CMS enzymes, and 1 mL fractions were collected in microcentrifuge 
tubes. All samples collected were subjected to protein determination. 
Protein Determination 
A Bio-Rad assay (Bio-Rad Inc.) was used to determine protein concentration in purified 
samples. The Bio-Rad Protein assay is based on the Bradford method (Bradford, 1976). The 
assay involves using an acidic dye, that upon binding of protein, shifts the absorbance of the dye. 
In the Bio-Rad assay, Coomassie Brilliant Blue G-250 dye has a λmax at 465 nm. When protein is 
added to a solution containing the dye, a shift in λmax is observed from 465 to 595 nm in response 
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to protein binding. The absorbance at 595 nm is linear with respect to protein concentration. A 
calibration curve using bovine serum albumin (BSA) from 0-20 μg was utilized.  
From each elution fraction 10-100 μL sample was diluted in 200 μL of Bio-Rad assay 
dye and enough water to achieve a total final volume of 1 mL. Each sample containing the Bio-
Rad dye and protein was analyzed using a UV-Vis spectrometer (Evolution 250 BIO by Fisher 
Scientific). When all fractions are analyzed, the fraction with the highest concentration of protein 
is chosen for the enzyme assay.  
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE), is a common 
method used for the separation of proteins by apparent molecular mass by applying an electric 
field across the gel (Laemmli, 1970). Lauryl sulfate (SDS) is an anionic detergent, which 
denatures protein and binds to the proteins to produce an overall negative charge. The negative 
charges on SDS are strongly attracted toward an anode (positively-charged electrode) in an 
electric field and cause the migration of protein through the gel. When proteins are denatured 
into their linear polypeptide chains, SDS molecules interact with each protein similarly so they 
contain uniform charge to mass ratios. The migration distance of each protein is inversely 
proportional to the log of its mass. Running a sample of protein standard that contains known 
molecular mass proteins on the same gel and plotting migration distance vs. the log molecular 
mass will produce a standard curve that can be used to determine unknown protein masses. A 
typical SDS-PAGE gel contains two portions, a resolving and a stacking gel portion. The 
stacking gel is the upper portion of the gel that is responsible for compressing the loaded protein 
sample into a thin layer prior to reaching the resolving gel. This allows all proteins to enter the 
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resolving gel at the exact same time. The resolving gel is the portion that is responsible for the 
separation of the polypeptides by mass.  
 Resolving and stacking gels were prepared for protein analysis. A 12% (wt/v) resolving 
gel was prepared by mixing 2.15 mL water, 1.5 mL of 40% acrylamide solution (Fisher), 1.25 
mL of 1.5 M pH 8 Tris buffer (USB Corporation), 50 μL of 10% SDS buffer (ACROS), 100 μL 
of freshly prepared 10% (wt/v) ammonium persulfate solution (APS) (Fisher Scientific), and 4 
μL of tetremethylethylenediamine (TEMED) (Fisher BioReagants). The APS is a source of free 
radicals that enhances the polymerization of acrylamide for gel formation. TEMED is used to 
stabilize free radicals which aids in the rapid rate of polymerization. The free radicals that are 
produced by APS react and form free radicals on acrylamide monomers that then react with other 
acrylamide monomers to polymerize. The acrylamide polymerization forms a porous gel that 
separates the proteins. The gel is prepared with a pH 8 buffer for more anionic glycine to slow 
protein migration and enhanced protein separation. The stacking gel was then poured between 
two glass plates with a layer of isopropanol and allowed to polymerize. The resolving gel is 
poured to leave approximately 1 cm of space for a stacking gel. A 4% (wt/v) stacking gel was 
then prepared with 1.5 mL of water, 250 μL of 40% acrylamide solution, 250 μL of 1.0 M pH 
6.8 Tris buffer (USB Corp.), 20 μL of 10% SDS buffer (ACROS), 40 μL of 10% APS (Fisher 
Scientific), and 4 μL of TEMED (Fisher BioReagants). The isopropanol layer was then removed, 
the stacking gel was poured, and well combs were placed between the plates for sample loading. 
The lower pH of the stacking gel favors zwitterionic glycine molecules to increase migration. 
 Protein samples were prepared by diluting pure protein sample with water and 4x SDS 
dye to a desired protein concentration. The 4x SDS dye is a solution containing 270 mM SDS 
(ACROS), 6 mM bromophenol blue, 200 mM Tris-HCl (USB), 400 mM dithiothreitol (ACROS), 
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and 40% (v/v) glycerol (Sigma-Aldrich). The desirable concentrations to load of pure protein is 
about 0.1 μg/μL and for mixtures of protein is 1.0 μg/μL. For pure protein ideal loading amount 
is 1-5 μg and for mixtures is 10 μg. Each loading well has the capacity to hold 20 μL of sample. 
Protein samples diluted for SDS-PAGE analysis were placed into a boiling water bath for 5 
minutes to encourage full denaturation and even coating of SDS molecules along the 
polypeptide. Protein standards and samples were loaded into the wells and electrophoresed at 
150 V for an hour or until the dye front runs off the gel. Following electrophoresis, the glass 
plates were removed and the gel placed into a staining solution. The staining solution contains 
Coomassie blue dye dissolved in 45% (v/v) methanol (Sigma) and 10% (v/v) acetic acid (Fisher). 
The staining container was placed on a rocker (Labnet International) at 2 RPM for 30 minutes. 
The gel was then removed from the staining solution and placed into a destain solution which is 
45% (v/v) methanol and 10% (v/v) acetic acid. The destain was then placed on the rocker at 2 
RPM to for 1-12 hours to remove any excess dye from the gel. Once destain solution was 
saturated with dye it was replaced with fresh solution. The gel was analyzed to obtain molecular 
mass information with target protein migration in comparison to known protein standards.  
Enzymatic Assay Procedure CMS 0235 
 CMS 0235 enzyme was diluted with nanopure water (exception of pH profile) to 0.020 
μg/μL, to ensure that when 5.0 μL of enzyme is added, the total enzyme in the assay is 0.10 μg. 
A previous study showed that using 0.10 μg of enzyme in an assay gives a good signal to noise 
ratio for measured product (Brault & Friesen, 2016). A stock solution of each of the substrates 
(MEP and CTP) was prepared to a concentration of 20 mM in H2O. Cytidine 5’-triphosphate 
disodium salt and 2-C-methyl-D-erythritol 4-phosphate lithium salt were obtained from Sigma-
Aldrich. A solution of 10 mM dithiothreitol (DTT) was prepared for the enzyme assay as well. 
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The purpose of DTT in an enzyme assay is to keep the protein in a reduced environment. An 
example would be to keep cysteine amino acids reduced on the protein surface as so to retain 
enzymatic activity. A final 10x reaction buffer solution was made of 250 mM imidazole 
(ACROS) and 500 mM magnesium acetate (EM Industries Inc.) adjusted to a pH of 7.4.  
 The first assay conducted was a time dependent assay. Ten microcentrifuge tubes were 
used as the reaction vessels for the enzyme assay. For the time dependent assay each tube was 
loaded with the following: 7 μL of water, 2 μL of 10 mM DTT, 2 μL of 20 mM CTP, 2 μL of 20 
mM MEP (Sigma-Aldrich), and  2 μL of 10x reaction buffer. The enzyme and reaction tubes are 
set to reach room temperature prior to addition of enzyme. Five μL of 0.020 μg/μL of CMS 0235 
were added to each tube to begin the reaction, and placed on a hot plate set to 37 oC. Every 3 
minutes a tube was removed and the enzyme reactions were terminated by placing the tubes in 
boiling water, which will denature the enzyme. Removing tubes every 3 minutes will cover a 
range of 0-30 minutes of reaction time. After each tube was allowed to boil for 5 minutes, the 
tubes are centrifuged at 15,000 RPM for 1 minute. This will pellet the denatured protein to the 
bottom of the microcentrifuge tube. HPLC vials (CG LifeSciences) were prepared by diluting 15 
μL of the enzyme reaction in 276 μL of water to have a total of 291 μL samples in each HPLC 
vial. The remainder of the kinetic assays were conducted for 15 minutes. 
 An assay was performed with varying concentrations of CTP while keeping the 
concentration of MEP at 2 mM in every reaction tube. Various concentrations of CTP were 
prepared from a 20 mM stock solution of CTP. The reaction tubes (in triplicate) were loaded 
similarly to the previous assay with the exception of CTP as concentration was varied with each 
tube. Upon addition of CMS 0235, each tube was allowed to incubate for 15 minutes. Reactions 
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were terminated and handled the same as the previous assay. Varying MEP enzyme assay was 
performed following the same procedure.   
 A pH profile of CMS 0235 was obtained. A 10x buffer of 500 mM Tris (pka= 8.07), 500 
mM glycine (pk1= 2.4 pk2= 9.6), 500 mM phosphate (pk1= 2.2, pk2= 7.2, pk3= 12.3) with 250 
mM MgCl2 was prepared and 20 mL aliquots were each adjusted to a desirable pH with NaOH 
or HCl. The buffers were prepared to cover a range of pH 4-12. A minor adjustment to the assay 
was the enzyme was aliquoted and diluted with 1x pH buffer to 0.020 μg/μL and properly 
labeled. Reaction tubes were prepared with 7 μL of water, 2 μL of 10 mM DTT, 2 μL of 20 mM 
CTP, 2 μL of 20 mM MEP, and  2 μL of 10x pH buffer. Reactions were initiated with the 
addition of 5.0 μL of enzyme. The assay was performed following the same procedure as above. 
 Various divalent cations were also tested for their effects on enzymatic activity. Various 
10x buffers were prepared containing 500 mM imidazole and 250 mM MCl2 (where M= Mg, Ba, 
Co, Ni, or Mn) adjusted to pH 7. Reaction tubes were prepared with 7 μL of water, 2 μL of 10 
mM DTT, 2 μL of 20 mM CTP, 2 μL of 20 mM MEP, and  2 μL of MCl2 10x buffer. Reactions 
were initiated with the addition of 5.0 μL of 0.020 μg/μL CMS 0235 and the tubes were 
incubated on a hot plate at 37 oC for 15 minutes. Reactions were terminated and handled the 
same as previous assays.   
Enzymatic Assay Procedure CMS 1086 
 An assay was completed to determine if product formation increased with increasing 
concentrations of CMS1086. The assay mixture still contained the same contents as CMS 0235, 
7 μL of water, 2 μL of 10 mM DTT, 2 μL of 20 mM CTP, 2 μL of 20 mM MEP, and 2 μL of 10x 
reaction buffer. Separate tubes were prepared with the assay mixture and then varying amounts 
of enzyme (0-1.3 μg CMS 1086) were placed in each tube to begin the reaction. The reaction was 
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allowed to incubate for 15 minutes and analyzed following procedures of CMS 0235. Product 
formation was low, but it was determined that 1.0 μg would be the optimal amount of enzyme for 
further assays. 
 A time variation assay was performed with 1.0 μg CMS 1086 over the range of 0-285 
minutes. For further assays a time of 150 minutes was selected. All further assays were 
conducted under the same procedure as CMS 0235 with the exception of time and amount of 
enzyme present in each tube.  
HPLC Calibration 
 A calibration curve was obtained using High Performance Liquid Chromatography 
(HPLC). Since the product of the reaction is not available for purchase, CDP-choline was used as 
the standard for the calibration. Using CDP-choline as the standard an assumption will be made 
that the product CDP-ME will approximately have the same molar absorptivity as CDP-choline. 
Figure 4 displays the calibrant molecule CDP-choline as well as CDP-ME, which is the product 
of the enzymatic reaction. The chromophore on both molecules are identical which is the reason 
CDP-choline was selected to be the calibrant. In separate microcentrifuge tubes were added 
varying concentrations of CDP-Choline from 0.00100-0.0500 mM and each tube contained 0.200 
mM CTP as well. Each tube was boiled for 5 minutes to simulate the enzyme assay procedure. 
After each tube had been boiled, HPLC vials were prepared containing 200 μL of standard and 
200 μL of nanopure water, and placed in the autosampler. HPLC conditions are the same as 
experimental with a 10 μL injection. A plot with nanomoles of CDP-choline injected vs. peak 
area is shown in Figure 5.  
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Figure 4. CDP-ME and CDP-choline Structures. Chromophore outlined in red and has an 
absorbance at 254 nm.  
 
 
Figure 5. HPLC Standard Curve. Peak area plotted as a function of CDP-Choline. Each point 
represents a single injection. 
  
y = 368x + 1.12
R² = 0.999
0
10
20
30
40
50
60
70
80
90
100
0 0.05 0.1 0.15 0.2 0.25 0.3
C
D
P
-c
h
o
lin
e
 P
e
a
k
 A
re
a
CDP-Choline (nmoles) injected
HPLC Calibration 
24 
HPLC Method Application 
 A modified version of a recently developed method for enzyme assay analysis using high 
performance liquid chromatography for cytidylyltransferase enzymes was utilized (Brault & 
Friesen, 2016). The study showed that the substrate, cytidine triphosphate (CTP) and product, 4-
diphosphocytidyl-2-C-methylerythritol (CDP-ME) are able to be separated using HPLC (Brault 
& Friesen, 2016). Prior assay methods included 14C radioisotope labelling and a colorimetric 
assay using malachite green as described by Jim Brault (Brault Thesis, 2016). Using HPLC as 
the preferred method allows detection of substrate and product directly. In order to utilize the 
malachite green assay, a phosphatase enzyme is required to convert the inorganic pyrophosphate, 
a byproduct of the enzymatic reaction, to free phosphate (Bernal, Palacin, Boronat, & Imperial, 
2005). The free phosphate is then reacted with the malachite green dye to produce a green 
product, which can then be determined spectrophotometrically. Also, HPLC advantages exist 
over the isotopic labeling due to more limited waste disposal as well as a more cost effective 
alternative for the assay (Brault & Friesen, 2016).  
 The HPLC that was used for analysis was a HP series 1100, containing an autosampler 
and a PDA Plus detector (HP/Agilent). The column used was a SunfireTM C18 with 
measurements of 4.6 mm x 15 cm and 5 μm particle size. A betasil C8 guard column was also 
assembled to prevent any contamination of the column and increase column lifetime.  
An aqueous mobile phase (0.10 M ammonium bicarbonate) was prepared to an adjusted pH of 
7.3, essential for column health and optimal separation of CTP and CDP-ME. The final mobile 
phase was 99% buffer and 1% acetonitrile. The HPLC was allowed to run for 45 minutes at 
0.500 mL/min to equilibrate the column with the mobile phase prior to sample injection. The 
spectra were monitored at 254 nm and the only optically active compounds in the reaction are 
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CTP and CDP-ME. An auto sampler was used to inject each sample with an injection volume of 
10 μL. Typical chromatograms represent a CTP peak eluting at 3.1 minutes and the product peak 
elutes at 4.7 minutes. Since mobile phase was prepared fresh daily it slight differences in peak 
elution times (CTP: 3.0-3.3 min. CDP-ME: 4.5-4.9 min.) were observed. The CDP-ME is 
slightly more nonpolar than CTP due to its loss of phosphate and addition of erythritol, which 
explains the later elution time on a RP-C18 column. 
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CHAPTER III: RESULTS AND DISCUSSION 
Expression and Purification of CMS 0235 and 1086 
CMS 0235 and CMS 1086 were both successfully expressed upon induction with IPTG. 
CMS 1086 is a 27.5 kDa protein and CMS 0235 is a 25.9 kDa protein each, with a 6x His-tag at 
the amino terminus.  SDS-PAGE (Figure 6) confirms that, upon induction by IPTG, the cells 
express the proteins, and bands are present in the expected regions of the gel between 25-37 kDa 
protein standards. Unfortunately, CMS 1086 was not soluble under the expression system of 
BL21 (DE3)CodonPlus RIL E. coli cells as shown by Shilpa Maroju in her thesis work (Maroju 
Thesis, 2008). Therefore, CMS 1086 was expressed in ArcticExpress (DE3) competent cells and 
successful expression was observed (Figure 7). 
 
Figure 6. SDS-PAGE of CMS 0235 and 1086 Expression Upon Induction of Cells with IPTG in 
BL21 (DE3) CodonPlus RIL E. coli Cells. “U” is uninduced, “I” is Induced. Red boxes indicate 
position of CMS 1086 (1086I) and 0235 (0235I) on the gel. CMS 1086 was insoluble using 
BL21 (DE3) CodonPlus RIL E. coli cells.   
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The ArcticExpress (DE3) RIL competent cells display a large band at about 57 kDa 
which is the Cpn60 subunit of the chaperonin protein (Figure 7). The Cpn10 subunit is about 10 
kDa and not easily identified on the SDS gel since lower molecular mass proteins are more 
difficult to identify. Purification gels of both CMS isoforms indicate that the elution fractions 
collected display the presence of a prominent band at the correct molecular mass (Figures 8 and 
9). The standards of each purification gel were plotted using the log of the molecular mass as a 
function of migration distance shown in Figures 10 and 11. Using non-linear analysis, the 
experimental values for molecular mass of CMS 0235 and 1086 extrapolated from the curve 
were 26.3 kDa and 28.4 kDa, respectively. These are near the theoretical molecular mass of 
CMS 1086 and 0235 since both of the proteins on the gel contain a 6x-His tag. The 10 mM 
imidazole wash removes some weakly bound proteins and a small amount of CMS visible on the 
gel. The enzymes are also found in the crude extract, supernatant (SUP), and column flow 
through (C.F.T). The C.E. is the cell extract following the cell lysis procedure which contains all 
soluble and insoluble materials. The SUP is aqueous sample after centrifugation and the pellet is 
the insoluble material formed upon centrifugation. The C.F.T is the sample collected after the 
SUP is flowed through the column, which at this point the CMS should be retained on the 
column. Each elution number corresponds to the 1 mL elution fraction from the column upon 
eluting enzyme. By SDS-PAGE analysis, it was determined that both CMS isoforms were 
successfully expressed and purified for enzyme kinetics. 
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Figure 7. SDS-PAGE of CMS 1086 Expression Upon Induction of Cells with IPTG in 
ArcticExpress (DE3) RIL E. coli Cells. “U” is uninduced, “I” is induced. Induced lanes display a 
band at around 30 kDa that is outlined in red while the uninduced lanes did not. This is an 
indication of successful expression of CMS 1086. Samples were loaded twice for clarity. 
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Figure 8. SDS-PAGE Purification Gel of CMS 1086. The large band at 57 kDa is the Cpn60 
subunit of the chaperone folding protein expressed in ArcticExpress (DE3) cells. The Cpn10 
subunit is not visible on the gel, which is theoretically about 10 kDa. 
 
 
Figure 9. SDS-PAGE Purification Gel of CMS 0235. Elution 1 and Elution 2 are the fractions 
collected from the column. 
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Figure 10. Plot of Log of Molecular Mass vs Migration from CMS 0235 Purification Gel. 
Experimental molecular mass of CMS 0235 was 26.3 kDa. 
 
 
Figure 11. Plot of Log of Molecular Mass vs Migration from CMS 1086 Purification Gel. 
Experimental molecular mass of CMS 1086 was 28.4 kDa. 
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Validation of HPLC 
 A recent study showed a successful separation of CTP and CDP-ME by using HPLC 
(Brault & Friesen, 2016). In the previous study, substrate CTP eluted at about 2.5 minutes and 
product CDP-ME eluted at 3.1 minutes. The HPLC conditions used by Jim Brault are outlined in 
his thesis (Brault thesis, 2016). In this current study, a modified method was used which included 
a guard column and a reduction of eluent (acetonitrile) from 2% to 1%. In this current work a 
SunfireTM C18 column was used with a betasil C8 guard column. A slight drop in pH to 7.3 from 
7.4 was used to provide sufficient separation and increase column health. Injection of CTP and 
CDP-Choline (Figure 12) resulted in sufficient separation with CTP elution at about 3.1 minutes 
and CDP-Choline elution time at 3.7 minutes. A second chromatogram in Figure 13 is the 
injection of CTP and CDP-ME (from an enzyme assay) and indicates a larger separation was 
achieved with CDP-ME eluting at 4.8 minutes. The successful characterization of two CMS 
enzymes in this thesis further validates this method for the characterization of 
cytidylyltransferase enzymes without the use of coupled assays or isotope labeling. 
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Figure 12. HPLC Chromatogram Injecting CTP and CDP-choline Monitored at 254 
Nanometers. Elution of CTP is at 3.117 minutes and CDP-choline elution peak at 3.653 minutes.  
 
 
Figure 13. HPLC Chromatogram Injecting CTP and CDP-ME Monitored at 254 Nanometers. 
Elution of CTP is at 3.296 and 3.497 minutes and CDP-ME elution peak at 4.786 minutes. Split 
peak for CTP is likely due to multiple protonation states of CTP. 
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CMS Enzyme Kinetics 
Studying enzyme kinetics is important to understanding catalytic mechanisms, drug 
inhibition, and enzyme regulation in metabolism. One of the hallmarks of enzyme kinetics is the 
experimental determination of kinetic constants Km and Vmax. These values are determined using 
the Michaelis-Menten equation, which is currently one of the most effective models for 
investigating enzyme kinetics. Michaelis-Menten kinetics states that the rate of reaction is 
dependent on substrate concentration, thus if substrate concentration increases, the rate of 
reaction increases as well. Eventually, increasing substrate concentration to the point of enzyme 
substrate saturation will reach maximum velocity. The point at which the reaction is considered 
to have reached a theoretical maximum of enzyme-substrate complex saturation is referred to as 
the Vmax. Using this model, Km is the substrate concentration at which the enzyme is functioning 
at ½ Vmax. Michaelis-Menten kinetics fits the model of one substrate and one product, although if 
the enzymes of interest have multi-substrate molecules this model can still be applied. In order to 
simplify the reaction and apply the Michaelis-Menten kinetics model, one substrate is held 
constant at a saturating concentration while the other substrate concentration is varied. Data were 
best fit using SigmaPlot (SYSTAT) nonlinear regression analysis, Lineweaver-Burk, Eadie 
Hofstee, and Hanes Woolf plots to determine the kinetic parameters Km and Vmax. 
Michaelis-Menten:  =
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Nonlinear regression analysis using SigmaPlot employed the Hill equation, which is a 
powerful tool for the investigation of allosteric regulation. Enzymes that have multiple subunits 
may undergo allosteric regulation, which is the effect that a substrate molecule binding to one 
active site has on the binding affinity of other molecules on other active sites. The Hill 
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coefficient is the “n” term in the Hill equation and provides information on the cooperative 
binding of each substrate. If the term is >1 it indicates positive cooperativity, thus a value of less 
than 1 indicates negative cooperativity, and a value equal to 1 reflects no cooperativity. Positive 
allosteric modulation occurs when the binding of one ligand enhances the attraction between 
substrate molecules and other binding sites. A negative cooperativity implies the opposite, that 
binding of one ligand decreases the attraction between substrate molecules and other binding 
sites, and no cooperativity suggests substrate molecules induce no effect on binding sites. 
 The conversion of CTP and MEP to CDP-ME as a function of enzyme (μg) for CMS 
1086 are reported in Table 1. Product formation was not detected using the HPLC until >0.8 μg 
of CMS 1086 was added to the reaction. The assay was conducted with a 15-minute incubation 
time, which was not long enough to detect satisfactory levels of product. CMS 0235 results for 
varying enzyme were completed in a recently published paper, thus not conducted for this thesis 
project (Brault & Friesen 2016). 
 
CMS 1086 in reaction (μg) Product Peak Area 
0.10 0 
0.40 0 
0.60 0 
0.80 0 
1.0 8.4 
1.5 13.4 
 
Table 1. Effects Of CMS 1086 Added To Reaction And Product Peak Formation. Assay 
incubation period was 15 minutes at 37 oC. 
 
The outcome of the CMS 0235 (0.10 μg) assay with time vs. product formation are 
plotted in Figure 14, with the linear portion replotted shown in Figure 15. This assay plot 
illustrates the reaction incubation time range where product formation is linear with respect to 
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time, identifying apparent 1st order kinetics. The line eventually reaches the asymptote, meaning 
with increasing enzyme incubation times, product formation is no longer a function of time. This 
portion is known to be the 0th order kinetics region. As previously mentioned, a 15 minute 
incubation period was selected for CMS 0235 as at this time the enzymatic reaction was still 
under apparent 1st order kinetics. Looking at the time dependent assay plot (Figure 16) for CMS 
1086, the x-axis (time in minutes) covers a much larger range (0-285 minutes). The much longer 
incubation time was necessary for CMS 1086 in order to detect product.  Figure 17 is the linear 
portion where CMS 1086 is also behaving under apparent 1st order kinetics. The time selected to 
perform further assays was 150 minutes. Table 2 outlines the enzyme parameters chosen to 
perform further assays. All assays were executed with final reaction volumes of 20 μL.  
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Figure 14. Product Formation vs. Time for CMS 0235. Product Peak Area is plotted as a 
function of time for CMS 0235 
 
.  
Figure 15. Linear Region of CMS 0235 Varying Time. This is the region where CMS 0235 is 
displaying 1st order kinetics behavior (time 0-20 minutes). 
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Figure 16. Product Formation vs. Time for CMS 1086. Product Peak Area is plotted as a 
function of time for CMS 1086. 
 
 
Figure 17. Linear Region of CMS 1086 Varying Time. This is the region where CMS 1086 is 
displaying 1st order kinetics behavior (time 0-180 minutes). 
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 Time of 1st order 
kinetics (min.) 
Amount of Enzyme 
(μg) 
CMS 0235 15 0.1 
CMS 1086 150 1.0 
 
Table 2: Overview Of Selected Assay Time Periods And Amount Of Enzyme Used. Final 
reaction volumes were 20 μL assay for CMS 0235 and 1086. 
 
Kinetic assays were completed with the varying substrate in individual assays to 
determine Km and Vmax values for each substrate and enzyme. The first assay was conducted with 
a constant concentration of MEP (2000 μM) and CMS 0235 (0.1 μg) while varying concentration 
of CTP in individual reaction tubes (Figure 18). A second assay was conducted, this time with a 
constant concentration of CTP (2000 μM) and enzyme (0.1 μg) while MEP was varied (Figure 
19). Data were collected and analyzed using the Hill equation to determine CTPKm to be 329 ± 
66.0 μM and CTPVmax was 2333 ± 230 nmol/min/mg of CMS0235. The Hill coefficient of the 
plot for varying CTP was reported to be 1.31, implying positive cooperativity for binding of 
CTP. For the substrate MEP MEPKm was 187 ± 7.37 μM and MEPVmax was 2631 ± 48.6 
nmol/min/mg of CMS0235. The Hill coefficient for MEP was calculated to be 1.96, thus 
implying strong evidence of a positive cooperative binding mode of MEP. 
Evaluation of CMS 1086 was performed similarly to CMS 0235. Upon data analysis 
using the Hill equation CTPKm was 950 ± 593 μM and CTPVmax was 19.2 ± 4.84 nmol/min/mg of 
CMS1086 (Figure 20). Results with the varying MEP assay determined MEPKm to be 763 ± 337 
μM and MEPVmax was 31 ± 5.42 nmol/min/mg of CMS1086 (Figure 21). Hill coefficients for 
varying CTP and MEP were 0.878 and 0.877 respectively. Both values are close to 1.0 implying 
both substrates are behaving in a little to non-cooperative binding mode. 
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Figure 18. Hill Equation Plot for CMS 0235 with Varying Concentrations of CTP. Each data 
point is a mean ∓ standard error for n=3 replicates. 
 
 
Figure 19. Hill Equation Plot for CMS 0235 with Varying Concentrations of MEP. Each data 
point is a mean ∓ standard error for n=3 replicates. 
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Figure 20. Hill Equation Plot for CMS 1086 with Varying Concentrations of CTP. Each data 
point is a mean ∓ standard error for n=3 replicates. 
 
 
Figure 21. Hill Equation Plot for CMS 1086 with Varying Concentrations of MEP. Each data 
point is a mean ∓ standard error for n=3 replicates. 
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Lineweaver-Burk Transformation 
Prior to the accessibility of powerful non-linear regression software (SigmaPlot), 
alternative methods were employed for determination of kinetic constants Km and Vmax. These 
methods are known as the Lineweaver-Burk, Eadie Hofstee, and Hanes Woolf plots, which were 
simple and useful methods for treatment of enzyme kinetics data. The Lineweaver-Burk plot is 
simply a double reciprocal plot of the Michaelis-Menten, thus yielding the equation shown 
below. The Lineweaver-Burk is a linear representation of the initial Michaelis-Menten plot and 
by using the Lineweaver-Burk (L.W.B) equation in  =  +  format, kinetic constants of Km 
and Vmax may be easily extrapolated. Figures 22-25 are L.W.B transformations for both enzymes 
and substrates.   
Lineweaver-Burk: 


=



[	]
+


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Figure 22. Lineweaver-Burk Transformation Plot for CMS 1086 for Substrate CTP. Units of 
Vmax and rate are specific activity (nmol/min/mg of enzyme). Each data point is a mean ∓ 
standard error for n=3 replicates. 
 
 
Figure 23. Lineweaver-Burk Transformation Plot for CMS 1086 for Substrate MEP. Units of 
Vmax and rate are specific activity (nmol/min/mg of enzyme). Each data point is a mean ∓ 
standard error for n=3 replicates. 
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Figure 24. Lineweaver-Burk Transformation Plot for CMS 0235 for Substrate CTP. Units of 
Vmax and rate are specific activity (nmol/min/mg of enzyme). Each data point is a mean ∓ 
standard error for n=3 replicates. 
 
 
Figure 25. Lineweaver-Burk Transformation Plot for CMS 0235 for Substrate MEP. Units of 
Vmax and rate are specific activity (nmol/min/mg of enzyme). Each data point is a mean ∓ 
standard error for n=3 replicates. 
  
y = 1.83E-01x + 3.15E-04
R² = 0.994
Km= 581 μM
Vmax= 3180
0
0.0005
0.001
0.0015
0.002
0.0025
0.003
0 0.002 0.004 0.006 0.008 0.01 0.012 0.014
1
/r
a
te
1/[CTP]
CTP Lineweaver-Burk 0235
y = 1.77E-01x + 1.15E-04
R² = 0.984
Km= 1540 μM
Vmax= 8700
0
0.0005
0.001
0.0015
0.002
0.0025
0.003
0.0035
0.004
0.0045
0 0.005 0.01 0.015 0.02 0.025
1
/r
a
te
1/[MEP]
MEP Lineweaver-Burk 0235 
44 
Eadie Hofstee Transformation 
An alternative option to data analysis can be obtained using another popular linear 
transformation plot called the Eadie-Hofstee plot. Plotting the reaction rate vs. the ratio of rate 
and substrate concentration will potentially yield a linear plot. The plot will provide us with Km 
as the negative slope of the line and Vmax is the y-intercept. Calculated kinetic parameters of Km 
and Vmax using the Eadie-Hofstee equation are shown in Table 3. Plots for both enzymes and 
substrates are shown in Figures 26-29. In Figure 25, the R2= 0.426 and would not appear to be a 
good option to extrapolate kinetic constants from, although in this case these constants did seem 
to agree with other methods shown in Table 3.  
Eadie-Hofstee :  = −

[	]
+  
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Figure 26. Eadie-Hofstee Transformation Plot for CMS 1086 for Substrate CTP. Units of Vmax 
and rate are specific activity (nmol/min/mg of enzyme). Each data point is a mean ∓ standard 
error for n=3 replicates. 
 
 
Figure 27. Eadie-Hofstee Transformation Plot for CMS 1086 for Substrate MEP. Units of Vmax 
and rate are specific activity (nmol/min/mg of enzyme). Each data point is a mean ∓ standard 
error for n=3 replicates. 
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Figure 28. Eadie-Hofstee Transformation Plot for CMS 0235 for Substrate CTP. Units of Vmax 
and rate are specific activity (nmol/min/mg of enzyme). Each data point is a mean ∓ standard 
error for n=3 replicates. 
 
 
Figure 29. Eadie-Hofstee Transformation Plot for CMS 0235 for Substrate MEP. Units of Vmax 
and rate are specific activity (nmol/min/mg of enzyme). Each data point is a mean ∓ standard 
error for n=3 replicates. 
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Hanes-Woolf Transformation 
The Hanes-Woolf plot is another linear transformation plot of the Michaelis-Menten 
equation for rapid determination of Km and Vmax. This plots the ratio of substrate concentration 
and reaction rate vs. the substrate concentration. Vmax is equal to 


 of the line and the x-
intercept of the plot is equal to -Km. Refer to Table 3 for the values calculated using this method. 
Hanes-Woolf plots were created for both enzymes and substrates (Figures 30-33). 
Hanes-Woolf : 
[	]

=


[ ] +


 
 
 
Figure 30. Hanes-Woolf Transformation Plot for CMS 1086 for Substrate CTP. Units of Vmax 
and rate are specific activity (nmol/min/mg of enzyme). Each data point is a mean ∓ standard 
error for n=3 replicates. 
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Figure 31. Hanes-Woolf Transformation Plot for CMS 1086 for Substrate MEP. Units of Vmax 
and rate are specific activity (nmol/min/mg of enzyme). Each data point is a mean ∓ standard 
error for n=3 replicates. 
 
 
Figure 32. Hanes-Woolf Transformation Plot for CMS 0235 for Substrate CTP. Units of Vmax 
are specific activity (nmol/min/mg of enzyme). Each data point is a mean ∓ standard error for 
n=3 replicates. 
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Figure 33. Hanes-Woolf Transformation Plot for CMS 0235 for Substrate MEP. Units of Vmax 
and rate are specific activity (nmol/min/mg of enzyme). Each data point is a mean ∓ standard 
error for n=3 replicates. 
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which introduces some complexity to accurately determining Km and Vmax values using linear 
transformation methods. 
 
 CMS 0235 CMS 1086 
 MEPVmax
 MEPKm 
CTPVmax 
CTPKm 
MEPVmax 
MEPKm 
CTPVmax 
CTPKm 
L.W.B 8700 1540 3180 581 22.9 399 12.7 441 
Hanes-Woolf 3070 340 3210 660 26.8 560 16.0 663 
Eadie-Hofstee 3070 312 2520 451 24.8 427 14.9 528 
Hill Equation 2631 187 2333 329 31.3 763 19.2 950 
 
Table 3. Calculated Values of Vmax and Km Using Linear Transformation Methods And The Hill 
Equation In SigmaPlot. All units of Km are μM and Vmax are specific activity (nmol/min/mg of 
enzyme). 
 
Evaluation of Km and Kcat of CMS 0235 and 1086 
To compare CMS 0235 and 1086, these enzymes have very different activity levels as 
can be seen within the data. Kcat values were calculated from Vmax for each enzyme and their 
individual substrates. Kcat is the turnover rate, number of product molecules formed by the 
enzyme per unit of time. The CMS 0235 MEPKcat is 1.13 s
-1 and the CMS 1086 MEPKcat is 0.0143 
s-1, which suggests that CMS 0235 converts MEP to product approximately 100x faster than 
CMS 1086. A similar observation is made with CTP as CTPKcat for CMS 0235 and 1086 are 1.00 
s-1 and 0.0088 s-1 respectively.  
Another worthy comparison are the Km values for each of the enzymes, as they provide 
information on enzyme substrate binding affinity. Equation 1 shows k1 as the association 
constant and k-1 is the dissociation constant for typical enzymes. Since k2 is assumed to be the 
rate limiting step and thus very small in comparison to k1 and k-1, the equation is allowed to be 
simplified by removing k2. This now shows that Km is directly related to the association and 
dissociation constants for an enzyme which correlates to binding affinity.  
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Equation (1)              =
("#$"%)
"$
=
"#$
"$
 
Since the Km values for CMS 0235 are lower for both substrates, this suggested that the 
enzyme may have stronger binding affinity for each substrate than the 1086 isoform. The larger 
Km for CMS 1086 is an indication the enzyme is having trouble binding the substrate properly 
most likely due to poor amino acid to substrate interactions. This is translated into having a 
larger k-1 and/or smaller k1. In the larger scope of enzymes, CMS 0235 and 1086 are not very 
efficient enzymes in respect to their turnover rates. Kinetic constants of Km and Kcat can be used 
to calculate catalytic efficiency. An enzyme’s catalytic efficiency (C.E.) is equal to 
'(

. The 
CTPC.E. for CMS 0235 and 1086 were calculated to be 3040 M-1s-1 and 9.26 M-1s-1, respectively. 
The MEPC.E. for CMS 0235 and 1086 were calculated to be 8248 M-1s-1 and 18.7 M-1s-1, 
respectively.  
A study was done on enzyme kinetics that used the Brenda database to obtain all Kcat 
values for 1942 various enzymes from prokaryotic and eukaryotic organisms (Bar-Even et al., 
2011). The median Kcat was determined to be 13.7 s
-1 which is 10x faster than CMS 0235 and is 
about 1000x faster than CMS 1086 at converting substrate to product. The same study obtained 
Km values of over 5000 enzymes and calculated the median Km of enzymes was 130 μM, and 
60% of all enzymes had values ranging from 10-1000 μM (Bar-Even et al., 2011). In comparison 
to these literature enzymes, CMS 0235 (CTP, MEPKm= 329, 187 μM) and CMS 1086 (
CTP, MEPKm= 
950, 763 μM) have “average” values. Catalytic efficiencies were also obtained and the median 
was determined to be 125,000 M-1s-1. This indicates that both CMS 0235 (CTP,MEPC.E= 3040, 
8248 M-1s-1) and CMS 1086 (CTP,MEPC.E= 9.26, 18.7 M-1s-1) are not efficient when compared to 
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the total enzyme pool. These parameters for an enzyme are limited by many factors such as, the 
type of metabolic pathway, number of substrates, nature of substrates, and the size of an enzyme. 
Although some of these parameters are “low” in regards to the average, it may be by a selective 
mechanism. All enzymes cannot improve kinetic parameters ad infinitum, as regulation is 
essential in maintaining homoeostasis. Overall, these enzymes exhibit lower enzymatic activities, 
but it may be that no evolutionary pressures have forced CMS enzymes to become more 
efficient. 
pH Profile of CMS 0235 and 1086 
Enzymes behave differently under changing pH conditions. pH evaluations of enzymes to 
obtain optimum activity are important into understanding the mechanistic behavior of substrate 
conversion to product. In some cases pH is a regulatory factor in enzymes and they may be up or 
downregulated with changing pH environments. The optimum pH for growth of Listeria 
monocytogenes is 7.0 and the pH tolerance is reported from 4.4-9.4 (Lado & Yousef, 2007). 
When varying pH, many things may occur, such as changes in protein structure, ionization states 
of amino acids, substrate stability, and substrate ionization state. Extreme pH conditions will lead 
to disruptions in higher orders of protein structure and may lead to protein denaturation. By 
varying the pH environment and modifying the ionization state of amino acid side chains, a 
correlation may be observed between ionized state and effects on an enzyme substrate affinity. A 
pH profile of both CMS 0235 and 1086 was obtained with a range of pH 4-12 (Figures 34-35). 
The pH profile of both enzymes was determined to be similar as they both exhibit pH optimum 
activity at pH 8.5. Both isoforms exhibit a pH tolerance range of about 7-10, as most of the 
activity is lost outside this pH range. Some unexpected results occurred in the basic conditions of 
the pH region. Both enzymes have a Mg2+ cofactor; in basic conditions Mg2+ is precipitated out 
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as Mg(OH)2, thus making it inaccessible for the enzyme. Since activity is retained in basic 
conditions, it may be that the magnesium ion is not in rapid equilibrium with the environment 
but rather more tightly bound in the active site of the enzyme. A second possibility is the Mg2+ 
does not play a large role in catalysis and may not be very essential to retain enzymatic activity. 
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Figure 34. pH Profile for CMS 0235 in Triplicate. Product formation represented as Product 
Peak Area as a function of pH. Error bars represent standard error n=3 replicates 
 
 
Figure 35. pH Profile for CMS 1086. Product formation represented as Product Peak Area as a 
function of pH. 
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Divalent Cation Exchange 
 Some enzymes require cofactors to perform catalysis. Cofactors can act in a variety of 
ways by enhancing protein stability, binding substrate, provide platform for oxidative/reduction 
chemistry and/or stabilizing transition state intermediates. Enzymes without their cofactors are 
called apoenzymes, which is an enzyme in its inactive form; however, not all enzymes require 
cofactors. In cases of fluctuating environmental conditions, certain metal cofactors may become 
scarce which would induce physiological stress on organisms. In some instances, the use of 
cations in enzymes is a tool for regulation by providing an on off switch for enzymes. When 
organisms grow in resource depleted environments they are often able to overcome the 
challenges associated with minimal resources. Some mechanisms in doing so include enzyme 
cofactor substitution. Cytidylyltransferases typically require a Mg2+ metal cofactor. Some 
isoforms of CMS are not responsive to various divalent cations while others are less sensitive to 
divalent cation substitution (Tsang et al., 2011; Gabrielsen et al., 2004). In this study we 
substituted the Mg2+ divalent cation in the assay buffer with Mn2+, Ni2+, Ba2+, and Co2+ for both 
isoforms of CMS. CMS 0235 and 1086 both responded similarly with each substituted cation 
(Figure 36). Exchanging the cofactor for Ba2+ responded the best, displaying moderate activity 
relative to Mg2+. Substitution of Ni2+ also revealed that both CMS isoforms are able to function 
with this metal cofactor. With Co2+ both isoforms displayed greatly reduced activities, suggesting 
this substitution is possible but not ideal. Manganese (II) resulted in the least activity, with only a 
mild retention of activity for CMS 0235 and no activity for CMS 1086. The results suggest these 
enzymes are di-cation dependent but still functional with a few other divalent cations. In times of 
stress without access to Mg2+, Listeria monocytogenes is likely able to incorporate other divalent 
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cations into CMS for survival. This can be an attributing factor for why L. monocytogenes has 
the ability to survive in numerous environments. 
 
Figure 36. Divalent Cation Assay Results. Normalized activity plotted as a function of divalent 
cation for CMS 1086 and CMS 0235. Each concentration of cation in the reaction was 25 mM. 
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Sequence Analysis of CMS Enzyme Isoforms 
 Kinetic analysis of enzymes, although vital to development of potent inhibitors and 
helpful in understanding mechanisms, is not the only technique necessary for characterization of 
enzymes. Enzymes are typically protein molecules that are synthesized by living cells to catalyze 
biochemical reactions. Not all enzymes are proteins, as there are known catalytic RNA 
(ribozymes) that are involved in RNA processing. Proteins are composed of amino acids that are 
linked together by peptide bonds and range from a few amino acids to thousands. Proteins are 
classified into orders of structure known as primary, secondary, tertiary, and quaternary 
structures. The simplest form of protein structure is the sequence of amino acids, which is known 
as the primary structure. A secondary structure of a protein is the next level of protein structure 
and is a segment of the protein that folds into a set conformation based on favorable near 
neighbor amino acid interactions. The most common secondary structures are β-sheets (parallel 
or antiparallel), α-helices, and β-turns. Tertiary structure is simply the three dimensional 
structure of a protein due to amino acid side chain and backbone interactions. Some proteins 
contain a fourth level of protein structure, which is when multiple subunits (which may be the 
same or different) of protein form a larger protein complex recognized as quaternary structure. 
An enzyme’s functionality is contingent on the integrity of the native protein folding 
conformation. If an enzyme is denatured so that some of the orders of protein structure are 
disrupted, activity may be lost. Some enzymes also contain cofactors (inorganic ions), 
coenzymes (vitamins, organic nutrients), and covalent modifications (phosphorylation, 
glycosylation) to regulate enzyme activity. Enzymatic activity is correlated with protein 
structure, and sequence analysis was conducted to elucidate possible explanations for varying 
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activities between isoforms of CMS. Refer to Table 4 for sequence alignment identification and 
locations. 
 
Sequence 
alignment ID 
PDB Code Accession 
Number 
Organism Enzyme Figure 
location 
lmo0235 - CAD00762 L. monocytogenes CMS 38,39,40,46 
lmo1086 - CAC99164 L. monocytogenes CMS 38,39,40,46 
lmo3F1C 3F1C CAC99164 L. monocytogenes CMS 38,39,40,46 
OUT00427 - OUT00427 L. planturm RCT 46 
Camjej - AL139079 C. jenjuni Hypothetical 
ispDF 
40 
Myctu  NP_218099 M. tuberculosis CMS 40 
Fratul - CAJ79964 F. tularensis CMS 40 
Athal - AAF43207 A. thaliana CMS 40 
Ecol, EcoliCM 1INI 1INI_A E.coli CMS 38,39 
Arabdop 1W77 1W77_A A. thaliana CMS 36 
Bsub5HS2 5HS2 5HS2_B B. subtilus CMS 46 
Atal2YC3 2YCS 2YC3_A A. thaliana CMS 46 
Ecol1VGT 1VGT 1VGT_A E. coli CMS 46 
Bsub4JIS 4JIS 4JIS_A B. subtilus RCT 46 
Spn2VSH 2VSH 2VSH_A S. pneumonicos RCT 46 
 
Table 4. Legend for Sequence Alignments And Their Location. PDB codes are given for known 
structures and accession numbers are provided. Also provided is the organism the enzyme is 
from and the enzyme type (CMS or RCT). ispDF is a bifunctional enzyme, a product of gene 
fusion (ispD + ispF). IspF is 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase or MCS 
from the MEP pathway.  
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Structures of CMS 0235 and 1086 from Listeria monocytogenes have not been reported, 
so a multiple sequence alignment was constructed with other known structural isoforms of CMS 
(Figure 38). Refer to Table 6 for key amino acid equivalents. Amino acids have varying 
properties, nonpolar, polar, aromatic, positively charged and negatively charged (Figure 37). 
Many of the amino acids for CMS across the three organisms (Listeria monocytogenes, E. coli, 
and Arabidopsis thaliana) are not “conserved”, meaning each protein contains the same amino 
acid at an analogous location. This shows that at many locations on an enzyme an amino acid can 
be mutated and have little to no effect on enzyme activity. The regions in black from all 
sequence alignments specify highly conserved amino acids at that specific location, and grey 
regions represent locations of similar amino acids. These conserved areas indicate amino acids 
that have a higher probability of being essential in catalysis, which may include binding of 
substrates (or coenzymes/cofactors) and/or providing protein structural features necessary for 
proper folding.  
Blue Amino Acids 
Amino acid locations highlighted in blue from Figure 38 are vital to the enzyme’s 
function and are theorized to be the active site amino acids responsible for catalysis (Richard et 
al., 2004). A mutant study was conducted by mutating each amino acid highlighted in blue, 
which resulted in little to no activity for the E. coli isoform of CMS (Richard et al., 2004). The 
study concluded that Arg 20, Lys27, Arg167 and Lys213 are largely involved in the stabilization 
of the intermediate (Richard et al., 2004). The R20K mutant lost 55% activity while R20A 
retained full activity. The authors comment that the Mg2+ is able to stabilize the intermediate and 
perform the role of Arg20 when it is absent (Richard et al., 2004). Amino acids Thr140, Asp106, 
Thr165, and Arg109 contribute to the binding and  
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Figure 37. Amino Acid Structures and Their Respective Three and One Letter Codes. Amino 
acids are displayed as their dominant species at pH 7. Red locations indicate side chains with 
ionizable functional groups. Structures were made using ChemDraw. 
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Figure 38. Multiple Sequence Alignment for Various Isoforms of CMS. lmo0235 is CMS 0235, 
studued in this thesis (CAD00762). lmo1086 is CMS 1086, studied in this thesis (CAC99164). 
lmo3F1C is a putative CMS structure (PDB: 3F1C). Arabdop is a CMS isoform in Arabidopsis 
thaliana (PDB: 1W77). EcoliCM is a CMS isoform from E. coli (PDB: 1INJ). Amino acids 
highlighted in blue play major roles in catalysis and have been studied by site directed 
mutagenesis (Richard et al., 2004). Red amino acids are involved in substrate binding of CTP but 
have not been tested by site directed mutagenesis. Purple amino acids make up the glycine rich 
loop that also plays a role in CTP binding. Purple amino acids also have not been tested by site 
directed mutagenesis. Refer to Table 4 for sequence alignment information. Sequence alignments 
were constructed using kalign (https://www.ebi.ac.uk/Tools/msa/kalign/) and boxshade 
(https://embnet.vital-it.ch/software/BOX_form.html). 
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stabilization of the substrate methylerythritol phosphate (MEP). Note that Thr140 is part of the 
interlocking arm and buries itself in the neighboring subunit. 
Red Amino Acids 
Amino acids highlighted in red in Figure 39 are amino acids involved in binding of 
substrate CTP (ribose and cytidine moiety only) (Richard et al., 2004). Amino acids in red have 
not been studied by site directed mutagenesis. These amino acids provide substrate selectivity for 
CTP versus other nucleotide triphosphates but are not associated with MEP binding. These 
selected amino acids require further analysis. 
Purple Amino Acids 
A glycine rich loop is relatively conserved in CMS enzymes, highlighted in purple in 
Figure 36. This location is known to play a role in binding substrate through backbone 
interactions with the cytidine and ribose moiety. In some cases backbone interactions do not 
need a conserved amino acid as the backbone of a protein is presumably the same regardless of 
amino acid. In this region it may be an exception since glycine and smaller amino acids lead to 
secondary structure that other amino acids are unable to provide. This may cause a proper 
alignment for backbone substrate interactions. In this thesis, in order to gain further details on 
substrate binding and catalytic function, analysis was performed using multiple isoforms of CMS 
that have been characterized.  
Summary of Results 
 This section serves the purpose of identifying regions of significant amino acid residues 
that are involved in CMS enzyme activity. The blue amino acids are found to be critical for 
enzyme catalysis. Mutagenesis studies revealed that activity is severely compromised when 
mutating blue amino acids (Richard et al., 2004). Red amino acids have not been tested with 
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mutagenesis studies, however it has been postulated that they sequester the ribose and cytidine 
moieties of CTP (Richard et al., 2004). Purple Amino acids is the glycine rich loop also 
displaying interactions with cytidine and ribose moieties of CTP. Table 5 summarizes an 
overview of amino acids and their interactions along with color code on sequence alignments. 
 
Amino Acid Interaction Location Amino Acid Color Moiety 
Lys27 Side chain Blue α-phosphate 
Lys213 Side chain Blue α-phosphate/MEP 
Arg20 Both Blue α-phosphate/MEP 
Gly82 Backbone Red Cytidine 
Asp83 Backbone Red Cytidine 
Arg85 Both Red Cytidine 
Ser88 Side chain Red Cytidine 
Ala107 Backbone Red Ribose 
Asp106 Side chain Blue MEP 
Arg109 Side chain Blue MEP 
Thr140 Both Blue MEP 
Pro13 Backbone Purple Ribose 
Ala15 Backbone Purple Cytidine 
Gly16 Backbone Purple Ribose 
Thr165 Side chain Blue MEP 
 
Table 5. Amino Acids From E. coli CMS (PDB: 1INJ) And Their Respective Substrate 
Interactions. Amino acid color is used for rapid identification in sequence alignments used in this 
chapter.  
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EcoliCM lmo0235 lmo1086 arabdop lmo3F1C 
P13 L8 L7 L10 L9 
A15 A10 G9 G12 G11 
G16 G11 G10 G13 G12 
R20 R15 R14 R17 R16 
K27 K22 K22 K24 K24 
G82 G81 G80 G81 G83 
D83 S82 T81 K82 E84 
R85 R84 R83 R84 R86 
S88 S87 T86 S87 T89 
D106 D105 D110 D105 D103 
A107 A106 A111 S106 A104 
R109 R108 R113 R108 R115 
T140 T138 T143 T138 T145 
T165 T161 T167 T162 T169 
K213 K209 K216 K210 K218 
 
Table 6. Amino Acid Equivalents From Various CMS Isoforms. 
 
Sequence Analysis of Listeria monocytogenes CMS Isoforms 
A structure of a Listeria monocytogenes CMS isoform was deposited into the Protein 
Data Bank (PDB 3F1C) (Patskovsky et al., 2008). In this thesis the Listeria CMS from the PDB 
will be referred to as CMS 3F1C. A multiple sequence alignment was constructed including the 
two isoforms of CMS (0235 and 1086) that were characterized in this project, and CMS 3F1C. 
The sequence alignment reveals a high percentage (78%) of conserved amino acids between 
CMS 1086 and 3F1C. Due to the high amount of conservation between them, it is likely that 
both of these enzymes are products of the same gene. However, the Listeria monocytogenes 
culture used to clone the gene used in this study was slightly different from the culture used by 
the other investigators cloning the genes used to produce the CMS 3F1C protein. As was shown 
in the results section of this thesis, both CMS 0235 and CMS 1086 displayed CMS enzyme 
activity, therefore it is expected CMS 3F1C would exhibit CMS activity. Since CMS 3F1C 
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resembles a more conserved sequence with CMS 1086, the overall activity expected would be 
similar to that of CMS 1086. So the question is, why is the activity of CMS 0235 much higher 
than the CMS 1086 for conversion of MEP to CDP-ME? 
Blue Amino Acids  
According to Figure 39 and Table 7, all of the amino acids speculated to exhibit active 
roles in catalysis (indicated in blue) are conserved between all 3 CMS isoforms. This is evidence 
that the variance in enzyme activity of CMS 0235 and 1086 is not from the key active site amino 
acids. 
Red Amino Acids 
Possible locations of interest are S82 and S87 of CMS 0235. These locations are essential 
for substrate binding of the cytidine and ribose moieties of CTP (Richard et al., 2004). The 
equivalent amino acids of S82 and S87 from CMS 0235 are T81 and T86 from CMS 1086 
respectively, indication that serine has been substituted for a threonine at both positions (Table 
X). Although serine and threonine are similar amino acids, both contain a hydroxyl group and 
are considered polar; they are different due to a methyl group on threonine. An argument could 
be that a slight variation in size may lead to the dissimilar levels of enzyme activity due to 
protein folding issues or steric hindrance caused by the threonine substitutions in CMS 1086. 
Also, G107 of CMS 0235 is equivalent to a A111 in CMS 1086 and A104 in 3F1C. Since this 
amino acid is involved in a backbone interaction it may be that the larger side chain of alanine is 
disrupting enzyme activity. Despite the amino acid differences addressed here, most of the amino 
acids are not conserved in other regions of the protein, and an in-depth structural analysis must 
be completed. Further inspection of S82, G106 and S87 of CMS 0235 may be important in 
evaluating enzyme activity.  
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Purple Amino Acids 
 Evaluation of the glycine rich loop from Listeria monocytogenes putative CMS enzymes 
reveals some subtle differences. In Table 7 the sites where amino acids are not conserved 
between CMS 0235, 1086, and 3F1C have been shaded in purple as they correspond to the 
purple amino acids in the sequence alignment. The equivalent amino acid of A10 from CMS 
0235 is G9 in CMS 1086. Here a substitution of a glycine for an alanine may cause a tremendous 
change in activity, even though both are considered nonpolar amino acids. Glycine is a special 
amino acid that contributes to protein structure in ways no other amino acid is capable of doing. 
Due to its small size and ability to facilitate tight turns it can position the backbone in various 
orientations. In the literature, this loop is reported to interact with the 2’ and 3’ hydroxyl groups 
on the ribose of CTP (Obiol-Pardo, Cordero, Rubio-Martinez, & Imperial, 2010). These 
interactions are backbone interactions, and this region consists of small amino acids essential for 
secondary protein structure. In addition, Q12 from CMS 0235, which is the equivalent of K11 in 
CMS 1086, is not conserved between the isoforms of CMS from Listeria. From the literature, 
this position has not been fully evaluated but seems to be of lesser importance in the glycine rich 
loop. Further assessment of this region is necessary. Since substrate interactions within the 
glycine rich loop are facilitated exclusively through backbone interactions, it reduces the 
probability of this region as the cause of poor activity for CMS 1086.  
Summary of Results 
 A sequence alignment of CMS 0235, 1086, and 3F1C provides some details that may be 
correlated to enzyme activity (Figure 39). The blue amino acids are conserved in all the potential 
isoforms, which indicates that the variation in enzymatic activities is not contingent on those 
locations. The red amino acids were different in CMS 1086 versus CMS 0235 at locations 82, 
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106 and 87 from CMS 0235, and should be evaluated further. Since 3F1C has not been 
kinetically characterized, no tangible conclusions can be drawn from this isoform yet. The purple 
amino acids display variations at 2 locations, where CMS 0235 contains an A10 and a Q12, CMS 
1086 contains a G9 and K11. All locations must be further evaluated. 
 
lmo0235 lmo1086 lmo3F1C 
L8 L7 L9 
A9 A8 A10 
A10 G9 G11 
G11 G10 G12 
Q12 K11 K13 
G13 G12 G14 
R15 R14 R16 
K22 K22 K24 
G81 G80 G83 
S82 T81 E84 
R84 R83 R86 
S87 T86 T89 
D105 D110 D103 
G106 A111 A104 
R108 R113 R115 
T138 T143 T145 
T161 T167 T169 
K209 K216 K218 
 
Table 7. Amino Acid Equivalents From CMS Isoforms In Listeria monocytogenes. Amino acids 
that are shaded indicate lack of conservation and match their corresponding colors in the multiple 
sequence alignment in Figure 39. 
  
68 
 
Figure 39. Multiple Sequence Alignment of Putative Listeria monocytogenes CMS Isoforms. 
lmo0235 is CMS 0235 (CAD00762). lmo1086 is CMS 1086 (CAC99164). lmo3F1C is the 
putative CMS structure (PDB: 3F1C). Blue locations signify amino acids involved in substrate 
binding (cytidine/ribose) and catalysis. Red locations are amino acids involved in substrate 
binding only. Purple region is the glycine rich loop. Refer to Table 4 for sequence alignment 
information. Sequence alignments were constructed using kalign 
(https://www.ebi.ac.uk/Tools/msa/kalign/) and boxshade (https://embnet.vital-
it.ch/software/BOX_form.html). 
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Sequence Analysis of CMS Isoforms with Known Kinetic Parameters 
 To further understand how amino acid variations may lead to observed kinetic activities 
of CMS isoforms, a sequence alignment was constructed using isoforms from various organisms 
(Figure 40). All CMS isoforms used in the sequence alignment have been characterized, and 
reported values of Kcat, Km, and assay method are displayed in Table 9. The Kcat values of the E. 
coli, Campylobecter jejuni, and Arabidopsis thaliana enzymes are about 10x higher than CMS 
0235 and about 1000x greater than CMS 1086. The differences in these values may be due to key 
amino acids that are conserved between the highly active enzymes versus less active isoforms. 
With these data it may be possible to elucidate amino acids that result in reduced activity of 
CMS 1086. 
Blue Amino Acids 
The amino acids that are directly involved in catalysis are conserved throughout all the 
CMS isoforms, suggesting the cause of reduced/activated activity of these enzymes is not due to 
amino acids involved in catalysis. 
Red Amino Acids 
Previously, positions S82, S87, and A106 of CMS 0235 were identified for further 
analysis. The equivalent of amino acid S82 in CMS 0235 is not conserved by CMS isoforms 
making this position a less likely suspect in reduced enzyme activity for CMS 1086. Variation in 
the type of amino acid at S82 of CMS 0235 includes polar, positively charged, and negatively 
charged thus suggests that S82 of CMS 0235 may be less significant. In addition, S82 of CMS 
0235 interacts through backbone interactions which makes the identity of the side chain 
irrelevant. An all-encompassing characteristic is the equivalent of CMS 0235 S82 in all other 
isoforms being a hydrophilic amino acid. This is an indication that the side chain of the amino 
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acid is solvent exposed on the exterior of the protein, which upon inspection of E. coli CMS 
(PDB: 1INJ) looks to be true. CMS 0235 S87 is not completely conserved between all the 
isoforms as well. The S87 of CMS 0235 is equivalent to T86 from CMS 1086 and the 
Mycobacterium tuberculosis CMS isoform (Myctu). Since Myctu displayed better binding 
affinity (CTPKm= 48 μM) for CTP and similar enzyme activity to CMS 0235 (
CTPKm= 329 μM), it 
can be assured that T86 of CMS 1086 is not an explanation for low enzyme activity. The S87 of 
CMS 0235 is expected to interact with the cytidine moiety of CTP through its free hydroxyl 
group on the side chain. Since threonine possess a free hydroxyl group as well, it may be able to 
facilitate the same interactions as serine. The A106 of CMS 0235 is conserved by all isoforms of 
CMS except the Campylobecter jejuni (S181 equivalent of A107 of CMS 0235) and Arabidopsis 
thaliana (V98 equivalent of A107 of CMS 0235) isoforms of CMS. Isoforms of CMS from 
Campylobecter jejuni and Arabidopsis thaliana displayed good enzymatic activity which shows 
these substitutions are viable. The alanine is only involved in backbone interactions making the 
exact identity of the amino acid less relevant. CMS 1086 also contained an equivalent alanine at 
this location rendering this site not the cause of reduced activity. To précis, by applying known 
kinetic parameters of various CMS isoforms and using multiple sequence alignments we were 
able to deduce that the S82, S87, and A106 of CMS 0235 equivalents in CMS 1086 were not the 
primary explanation for poor activity. Nevertheless, further experimental analysis is expected at 
these locations to verify these results. 
Purple Amino Acids 
The glycine rich loop displays variation in many of the amino acids within this region 
including L8, A10, and Q12 from CMS 0235. The first position (L8 in CMS 0235) along the 
glycine rich loop is not conserved with three isoforms (Ecol, Myctu, and Fratul) containing an 
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equivalent proline. Using the kinetic data, no trends can be made between the three isoforms that 
contain a proline and those that do not, implying that this position is likely not responsible for 
reduced activity of CMS 1086. The next position in the glycine rich loop that is not fully 
conserved is the A10 of CMS 0235. CMS 1086 and the Arabidopsis thaliana (Athal) isoforms 
contain an equivalent glycine at this location. Since the Athal isoform displays a 1000-fold 
increase in MEPKcat over CMS 1086 but both contain glycine at this position, this is an indication 
that this location is not the primary cause of compromised activity in CMS 1086. The final 
position along the glycine rich loop which is Q12 of CMS 0235 is not conserved between any 
isoforms except Athal. This location is highly variable amongst isoforms as all types of amino 
acids are located at the Q12 equivalent of CMS 0235. As mentioned earlier, this location has not 
been well understood and is visible in protein crystal structures. Other locations in the glycine 
rich loop are well conserved, ruling out this region as a potential indication for varied activity of 
CMS 1086. Overall, L8, A10, and Q12 from CMS 0235 are not likely to be interfering with 
CMS 1086 activity. 
Green Amino Acids 
A protein modeling and computational experiment was employed to rationalize the 
increased binding affinity the Mycobacterium tuberculosis isoform of CMS has for substrates 
CTP and MEP (Obiol-Pardo et al., 2010). Using “Myctu” in the alignment, the outcomes suggest 
that amino acids responsible for increased binding affinity are T141 (T141 remained blue in 
Figure 40), I142, D193, and T84. D193 and T84 were suspected to coordinate Mg2+ while T141 
and I142 were expected to help stabilize the dimerization of the protein and improve binding 
affinity (Obiol-Pardo et al., 2010). Since T141 is conserved with all isoforms this site is not of 
concern for further evaluation. The Campylobecter jejuni CMS has the highest binding affinity 
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(MEP,CTPKm= 20, 3 μM) suggesting it has the best binding affinity of all the CMS isoforms and 
does not contain an equivalent threonine or isoleucine at T84 and I142 from Myctu. This 
suggests that the mechanisms of Mg2+ binding for these isoforms may in fact be different. At 
position D193 of Myctu, CMS 1086 contains an equivalent A194. This is a possible location of 
reduced enzyme activity since the other isoforms contain a negatively charged amino acid while 
CMS 1086 has a nonpolar alanine. According to structural analysis the E. coli isoform does not 
contain protein to Mg2+ interactions, so it may be that Myctu D193 is less relevant in other 
isoforms (Richard et al., 2004). Without protein structures of CMS 0235 and 1086, these sites 
becomes more difficult to make confident conclusions from. Without validating the proposed 
importance D193, I142, and T84 of Myctu by site directed mutagenesis it is not possible to make 
a conclusion on these amino acids. 
Summary of Results 
In this section, it has been reinforced that blue amino acids are still conserved and are not 
the suspected cause of reduced enzyme activity for CMS 1086. This sequence alignment shed 
light on the relative importance of the red amino acids as well. It was concluded that S82, S87, 
and A106 of CMS 0235 which are equivalent to T81, T86, and A111 in CMS 1086 are likely not 
causing poor activity in CMS 1086. The purple amino acids also revealed that L8, A10, and Q12 
from CMS 0235 and their respective equivalents in CMS 1086 (L7, G9, and K11) are also not 
expected to reduce enzyme activity in CMS 1086. This introduces evidence that none of the 
purple amino acids are liable for the reduced activity in CMS 1086. Now that all blue, red and 
purple amino acid locations have been ruled out as rationale for poor activity of CMS 1086, this 
leaves the green amino acids as potential problems. As mentioned the green amino acids were 
73 
determined to be important computationally but available structures of E. coli CMS (PDB: 1INI) 
do not support the claims observed computationally.  
Using a sequence alignment alone may be inadequate to elucidate the cause of variations 
in activity for CMS isoforms, therefore site directed mutagenesis studies are of high value to 
confirm some proposed amino acids involved in dimer stability. In addition, kinetic assay 
methods are not identical; it is difficult to assess the values properly with variability in assay 
method. Assay methods such as malachite green are not direct detection of product formation, 
but a coupled enzymatic assay using a second enzyme to achieve detection. Variations in assay 
procedures include divalent cation, buffer system, and pH, making a direct comparison of kinetic 
parameters problematic. Refer to Table 9 and 10 for the experimental conditions of various 
kinetic assays. 
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Ecol lmo0235 lmo1086 Athal Fratul Myctu Camjej 
P13 L8 L7 L84 P9 P13 L9 
A14 A9 A8 A85 A10 A14 A10 
A15 A10 G9 G86 A11 A15 A11 
G16 G11 G10 G87 G12 G16 G12 
F17 Q12 K11 Q88 I13 S17 N13 
G18 G13 G12 G89 G14 G18 G14 
R20 R15 R14 R91 R16 R20 R16 
K27 K22 K22 K98 K23 K27 K23 
G82 G81 G80 G154 G79 G80 G73 
D83 S82 T81 K155 E80 S81 D74 
R85 R84 R83 R157 R82 R83 R76 
A86 Q85 N84 Q158 F83 T84 A77 
S88 S87 T86 S160 S85 T86 S79 
D106 D105 D110 D180 D106 D107 D97 
A107 A106 A111 S181 A107 A108 V98 
R109 R108 R113 R183 R109 R110 R100 
T140 T138 T143 T212 T141 T141 T129 
M141 V139 I144 I213 V142 I142 - 
T165 T161 T167 T236 T164 T165 T147 
E191 E187 A194 D162 E192 D193 D169 
K213 K209 K216 K284 K214 K215 K191 
 
Table 8. Amino Acid Equivalents From CMS Isoforms With Known Kinetic Parameters. Amino 
acids that are shaded indicate lack of conservation and match their corresponding colors in the 
multiple sequence alignment in Figure 40.  
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Figure 40. Multiple Sequence Alignment From Kinetically Characterized CMS Enzymes. Blue 
locations signify amino acids involved in substrate binding (cytidine/ribose) and catalysis. Red 
locations are amino acids involved in substrate binding only. Purple region is the glycine rich 
loop. Green location is suspected to coordinate Mg2+ and stabilization of interlocking arm in 
Myctu. Athal is an Arabidopsis thaliana CMS. Fratul is the Francisella tularenisis CMS 
isoform. Ecol is the E. coli isoform of CMS. lmo 0235 and 1086 are the CMS isoforms studied in 
this thesis. Myctu is the Mycobacterium tuberculosis isoform of CMS. Camjej is a 
Camplylobecter jejuni hypothetical CMS bifunctional enzyme. Refer to Table 4 for sequence 
alignment information and accession numbers. Sequence alignments were constructed using 
kalign (https://www.ebi.ac.uk/Tools/msa/kalign/) and boxshade (https://embnet.vital-
it.ch/software/BOX_form.html).  
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Table 9. Kcat and Km Values of CMS from Multiple Organisms 
 
Organism pH/Buffer/Cation 
E. coli 7.8/Tris-HCl (398 nmol), MgCl2 (40 nmol), 
NaOH (79 nmol), and inorganic 
pyrophosphatase 0.7 unit/ Mg2+ 
Francisella tularenisis 8.0 / 100 mM Tris 1 mM MgCl2 100 mU/mL 
inorganic pyrophosphatase / Mg
2+ 
Mycobacterium tuberculosis 8.0 / 50mM Tris, 2 mM MgCl2 / Mg
2+ 
Listeria monocytogenes lmo0235 7.5 / 50 mM imidazole 25 mM Mg(OAc)2 / 
Mg2+ 
Listeria monocytogenes lmo1086 7.5 / 50 mM imidazole 25 mM Mg(OAc)2 / 
Mg2+ 
Campylobecter jejuni 8.0 / 100 mM Tris 1 mM ZnCl2 / Zn
2+ 
Arabidopsis thaliana 8.0 / 100 mM Tris, 5 mM MgCl2 0.1 unit 
inorganic pyrophosphatase / Mg2+ 
 
Table 10. Variability In Assay Buffer From Literature Experiments. Buffer system for each 
enzyme assay used to determine kinetic constants from Table 9. 
  
Organism MEPKcat MEPKm 
(μM) 
CTPKcat CTPKm 
(μM) 
Assay 
Method 
Reference 
E. coli 25.9 760 54.1 370 14C Richard et 
al., 2004 
Francisella 
tularenisis 
1 73 0.8 178 Malachite 
Green 
Tsang et 
al., 2011 
Mycobacterium 
tuberculosis 
N/A 92 0.8 43 Malachite 
Green 
Shi et al., 
2007 
Listeria 
monocytogenes 
lmo0235 
1.13 187 1 329 HPLC This Study 
Listeria 
monocytogenes 
lmo1086 
0.0143 763 0.0088 950 HPLC This Study 
Campylobecter 
jejuni 
13 20 N/A 3 13C NMR Gabrielsen 
et al., 2004 
Arabidopsis 
thaliana 
26 500 N/A 114 HPLC Rohdich et 
al., 2000 
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Structural Homology Modeling of CMS 0235 and 1086 
Sequence alignments are useful in the determination of active site amino acids and the 
effects sequence variability has on kinetic abilities of enzymes. However, structural modeling is 
another tool that may provide information as to why activities of isoforms are different. As 
mentioned before, catalytic activity of an enzyme is contingent on protein folding in a proper 
conformation. Protein modeling was conducted using Biozentrum SWISS-MODEL (Swiss 
Institute of Bioinformatics). This software takes an inputted amino acid sequence and matches it 
to amino acid sequences that have known structures deposited into the PDB. The amino acid 
sequence can then be modeled into 3-D structures using the PDB structures as templates.  
 Five PDB structures were selected to be used as templates for modeling CMS 0235. 
Modeled versions of CMS 0235 were analyzed using RasMol (Figure 40). One of the templates 
used to model the CMS 0235 was a ribitol-5-phosphate cytidylyltransferase (PDB: 4JIS). In 
comparison, the structures that were modeled all have similar overall secondary and tertiary 
structure. Table 11 shows the total number of helices, sheets, and turns that were modeled for the 
CMS 0235 protein. These numbers, although not identical, provide information that some 
regions of the enzyme that were random coiled in the template structure have defined secondary 
structure in CMS. These differences are not major, as it is not rare that a short sequence of amino 
acids is able to form a region of secondary structure depending on favorable amino acid side 
chain interactions. 
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Figure 41. Modeled Protein Folding of CMS 0235 Using SWISS-MODEL. Images created using 
RasMol. Blue regions indicate α-helices, yellow regions are β-sheets, and grey strings are 
random coil. (a) CMS 0235 modeled using PDB 5HS2. (b) CMS 0235 modeled using PDB 
2YCS. (c) CMS 0235 modeled using PDB 1VGT. (d) CMS 0235 modeled using PDB 3F1C. (e) 
CMS 0235 modeled on PDB 4JIS, a putative ribitol 5-phosphate cytidylyltransferase. The white 
box is the region of the interlocking arm, red box indicates the P-loop, and green boxes are the 
approximate location of the active sites. 
  
79 
When modeling CMS 1086 the template protein that displayed the highest sequence 
homology was a ribitol-5-phosphate cytidylyltransferase (RCT) from Bacillus subtilis (PDB: 
4JIS). This result opened up possibilities that the CMS 1086 may be a RCT rather than a MEP 
cytidylyltransferase. Comparing all structures modeled relative to a RCT, it was still difficult to 
address locations that would differentiate enzymes structurally. Looking at Figure 42, the RCT 
model looks to have lower protein order in the interlocking arm region. This difference is slightly 
visible but 5 models is a small sample size and the difference may not be the cause of poor 
activity of CMS. Table 12, shows the total number of helices, sheets, and turns that were 
modeled for the CMS 1086 protein. 
 
CMS 0235 Helices Sheets  Turns 
5HS2 21 28 38 
2YC3 18 26 41 
4JIS 22 24 45 
1VGT 19 27 46 
3F1C 22 26 44 
 
Table 11. Secondary Structure Elements For CMS 0235. Number of secondary protein structure 
elements present for CMS 0235 modeled on proteins using SWISS-MODEL.  
  
CMS 1086 Helices Sheets  Turns 
5DDT 21 26 46 
2YC3 20 26 51 
4JIS 19 24 43 
1VGT 23 28 46 
3F1C 22 24 43 
 
Table 12. Secondary Structure Elements For CMS 1086. Number of secondary protein structure 
elements present for CMS 1086 modeled on proteins using SWISS-MODEL. 
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Figure 42. Modeled Protein Folding of CMS 1086 Using SWISS-MODEL. Images created using 
RasMol. Blue regions indicate α-helices, yellow regions are β-sheets, and grey strings are 
random coil. (a) CMS 1086 modeled using PDB 5DDT. (b) CMS 1086 modeled using PDB 
2YCS. (c) CMS 1086 modeled using PDB 1VGT. (d) CMS 1086 modeled using PDB 3F1C. (e) 
CMS 1086 modeled on PDB 4JIS, a putative ribitol cytidylyltransferase. The white box is the 
region of the interlocking arm, red box indicates the P-loop, and green boxes are the approximate 
location of the active sites 
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Sequence/Structural Analysis of CMS and RCT Enzymes 
A study that specified some key amino acids that are conserved in ribitol 
cytidylyltransferase enzymes implicated T145, G167, and D137 of Spn2VSH as providing 
substrate specificity for a ribitol 5-phosphate (Baur et al., 2009). These amino acids are 
responsible for creating a deeper and more hydrophilic binding pocket (Baur et al., 2009). The 
reaction catalyzed by RCT alongside that catalyzed by CMS is shown in Figure 43. The 
substrates ribitol 5-phosphate (RboP) and MEP are similar but the RboP is more polar and longer 
than MEP, suggesting the need for a deeper and more polar binding pocket. The MEP 
cytidylyltransferase enzymes do not contain an equivalent of G167 and D137 from Spn2VSH but 
rather nonpolar amino acids such as Ile, Ala, and Val depending on the isoform in question. 
Figure 46 shows a multiple sequence alignment with 3 ribitol cytidylyltransferases, and 3 MEP 
cytidylyltransferases, CMS 0235, 1086, and 3F1C. The T145 of Spn2VSH is conserved by all 
the enzymes, however, the G167 and D137 of Spn2VSH are conserved between the 3 RboP 
cytidylyltransferase enzymes, CMS 1086, and 3F1C. Figure 44 displays the potential changes of 
the active site pocket when glycine and aspartate are substituted for their equivalents, A163 and 
I132 of E. coli CMS (PDB: 1INI), respectively. Figure 45 also illustrates the binding pocket of 
CMS using a surface map to better visualize the effects of alanine in the binding pocket. A 
portion of the structure/sequence is missing in all the CMS enzymes in this alignment outlined 
by a green box (Figure 46). For RCTs this region contains a slightly larger α-helix that the CMS 
enzymes do not have but the region is in a remote location. This region currently is not well 
studied although this location is a fingerprint region that may differentiate RCTs and MEP 
cytidylyltransferases. The study also revealed that the RCT from S. pneumonia is active against 
MEP, although physiologically irrelevant (Baur et al., 2009). S. pneumonia does not contain any 
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enzyme homologs from the MEP pathway but rather contains the genes from the mevalonate 
dependent pathway. In this section, evidence is provided that CMS 1086 represents better 
sequence homology with RCTs than MEP cytidylyltransferases.   
 
 
Figure 43. Reaction Catalyzed by Ribitol 5-phosphate Cytidylyltransferase and CMS. (a) 
Reaction catalyzed by a CMS enzyme. (b) Reaction catalyzed by a RCT. Images were 
constructed using ChemDraw. 
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Figure 44. RasMol Models of Partial Active Site Structures From Deposited PDB Files. (a) 
Structure of E. coli CMS complexed with CDP-ME (spacefill) and distance of 6.60 A (PDB 
1INI). Alanine and isoleucine are both hydrophobic amino acids that are located within the 
binding pocket (b) Structure of a known ribitol 5-phosphate cytidylyltransferase from 
Streptococcus pneumonia (PDB 4VSH), CDP-ME artificially for comparison purposes. Binding 
pocket contains aspartate and glycine allowing selectivity for larger hydrophilic substrates (c) 
Structure of putative CMS from Listeria monocytogenes (PDB 3F1C), product CDP-ME also 
artificially placed. This structure also contains aspartate and glycine. Comparing the binding 
region, it is clear that substitution of glycine for alanine creates a larger binding pocket an 
indication of substrate specificity for RboP. A substitution of aspartate for isoleucine also creates 
hydrophilic character, also an indication for RboP specificity. 
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Figure 45. Partial Active Site Surface Map of CMS from E. coli (PDB: 1INI). PDB ligand 
explorer generated picture displaying the short H-bond interaction from the carboxy backbone to 
the terminal hydroxide of MEP. A surface map is also shown to identify the steric hindrance the 
methyl group on A163 causes. If a longer more polar RboP was introduced into the binding 
pocket the methyl group creates a smaller binding pocket. A glycine is conserved at this location 
for RCTs which would remove the methyl group and open up the binding pocket creating more 
room to accommodate a larger substrate.  
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Figure 46. Multiple Sequence Alignment of Ribitol Cytidylyltransferases and MEP 
Cytidylyltransferases. Multiple sequence alignment including three RboP cytidylyltransferases 
(Spn2VSH, OUT00427, and Bsub4JIS), three methylerythritol cytidylyltransferases (Bsub5HS2, 
Atal2YC3, and Ecol1VGT), and the experimental CMS isoforms (lmo0235 and lmo1086). Red 
locations indicate regions of highly conserved locations for RboP cytidylyltransferases. 
Sequence alignment indicates CMS 1086 and PDB 3F1C, a putative methylerythritol 
cytidylyltransferase, contain conserved locations with RboP cytidylyltransferases. Refer to Table 
4 for sequence alignment information. Sequence alignments were constructed using kalign 
(https://www.ebi.ac.uk/Tools/msa/kalign/) and boxshade (https://embnet.vital-
it.ch/software/BOX_form.html).  
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Summary of Results 
When using the PDB structures as a template, some of the amino acids involved in 
binding substrate and in catalysis were not found in the original structure. Similarly, most of the 
CMS structures that are deposited into the database are found to be missing the same region of 
protein, which is usually about 15 amino acids following the glycine rich loop. Since these are 
X-Ray structures using diffractometric techniques, it may be concluded that this portion of the 
protein is mobile or disordered in a protein crystal. 
The underlying theme to all the structures, for both CMS and RCT, is a homodimeric 
protein that contains the interlocking arm and a P-loop region. This P-loop region is suspected to 
be an allosteric regulator acting like a seesaw opening and closing the active site upon substrate 
binding (Jin et al., 2016). Further work must be completed on the P-loop region as it serves an 
important role and may be the cause of allosteric cooperative binding observed for CMS 0235.  
Also, all the structures contain a modified version of the Rossmann motif, which is not surprising 
since it is commonly found in proteins that bind nucleotides. Overall, a structural sequence 
homology analysis revealed that both putative CMS enzymes (CMS 0235 and 1086) are very 
well modeled on various CMS isoforms from multiple organisms. However, structural homology 
modeling coupled with sequence analysis represents evidence that CMS 1086 is a putative RCT 
and not a CMS.  
 Evidence using structural modeling and sequence alignments indicate that CMS 1086 and 
lmo3F1C contain conserved amino acids with known RCTs. These amino acids were Spn2VSH 
equivalents of G167 and D137 that created a larger binding pocket favorable for the binding of 
RboP.  
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CHAPTER IV: CONCLUSIONS 
The MEP pathway remains a great source for novel biochemistry and targets for 
antibiotic drug development. Developing and improving assay techniques such as HPLC 
contributes innovative ways that allow for the analysis of enzymes. Both enzymes characterized 
in this project displayed kinetic activity acting as a CMS by converting substrates, MEP and 
CTP, to product CDP-ME. The CMS 0235 was concluded to be the much more efficient enzyme 
in comparison to CMS 1086. The catalytic efficiency for CMS 0235 for substrates CTP and MEP 
were determined to be 3040 M-1s-1 and 8248 M-1s-1, respectively. Catalytic efficiencies for CMS 
1086 with substrate CTP and MEP were calculated to be 9.26 M-1s-1 and 18.7 M-1s-1, 
respectively. This is a measure of how efficient enzymes are at catalysis. Data show that the 
catalytic efficiency for CMS 0235 is about 300x larger than that of CMS 1086. The sequence 
analysis of CMS isoforms revealed some information on the trends of catalytic activity and 
conserved amino acids. The structure homology and sequence analysis established some 
rationale for the poor activity of CMS 1086 by modeling against a ribitol 5-phosphate 
cytidylyltransferase (RCT). CMS 1086 was best modeled using a RCT, supplying evidence that 
CMS 1086 is a putative RCT enzyme. Using the model and providing sequence alignments of 
CMS isoforms and putative RCTs, CMS 1086 displayed similarities with RCTs that the CMS 
0235 did not. 
CMS 1086: A Ribitol Cytidylyltransferase? 
An overall conclusion from sequence alignment and structural modeling is that CMS 
1086 is a putative RCT and not a CMS. The National Center for Biotechnology Information 
(NCBI) reported CMS 1086 as a CMS gene in Listeria monocytogenes (Tettelin et al., 2000). 
Only recently (September 2017) was it identified to be a putative RCT from Listeria 
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monocytogenes after a shotgun genomic project was completed (Casey et al., 2016). If CMS 
1086 is a RCT, why would it catalyze the CMS reaction, albeit poorly? In this case, it is not a 
surprise it was able to behave like a CMS, using MEP and CTP to form CDP-ME. The substrate 
RboP and MEP have related features as that the CMS 1086 is able to recognize MEP as a 
substrate as well, and catalyze the reaction using MEP and CTP. During homology modeling and 
sequence alignments it was determined that these enzymes are structurally similar and this is a 
contributing factor for CMS 1086 to display CMS activity. Active sites of RCTs are larger and 
the binding pocket is more hydrophilic due to the smaller glycine and hydrophilic aspartate 
specific for RboP (Baur et al., 2009). Amino acids in the active site from both RCT and CMS are 
conserved, entailing that the mechanistic properties are similar if not identical. Further studies 
must be done to expose more properties of both enzymes to better differentiate them, as it is clear 
the scientific community is having difficulty differentiating CMS from RCT. Using automated 
gene prediction methods and protein homology is not sufficient in estimating gene products. In 
this thesis we have demonstrated that CMS 1086 is active against MEP but displays some 
structural features consistent with RCTs. 
Future Work 
 The work following the results of this project are to confirm CMS 1086 is a RCT. It 
would also be useful to clone the gene encoding the putative CMS (PDB 3F1C) from Listeria 
monocytogenes which, according to sequence analysis, may be a RCT as well. Enzyme assays 
should be completed with CMS 1086 and the 3F1C to validate their identities as a CMS or RCT.  
 An additional useful study is to perform site directed mutagenesis experiments on 
purported amino acids directly associated with enzyme function. Computational models are a 
starting point for analysis but results are based on theoretical calculations and not direct 
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observations. Evaluation of the enzymes for dimensions of the active site cavity and postulate 
why RboP or MEP are the preferred substrates. Some interesting questions leading into the 
future of this project are, is CMS 1086 a RCT, and if so, which amino acids are involved in the 
catalysis? Is it possible to mutate the amino acid(s) to open up the binding pocket and switch the 
enzyme into being either a RCT or a CMS? Also a RCT has not yet been characterized using the 
HPLC method, so the ability to separate product and substrate is still unknown. 
 The project is also open to developing potent inhibitors of CMS 0235 for the 
development of antibacterial therapeutics. Obstacles must be overcome in order to design potent 
inhibitors of CMS. This enzyme utilizes CTP as a substrate and a sugar derivative, which are 
abundant in all organisms. The dangers of applying a competitive inhibitor approach are evident, 
as many enzymes utilize CTP as a substrate. Applications of non-competitive, uncompetitive, 
and mixed competition inhibitors should be explored. This thesis lays a foundation for the 
development of next generation therapeutics from CMS in Listeria monocytogenes as a potential 
target.  
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